KR20220039189A - Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof - Google Patents

Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof Download PDF

Info

Publication number
KR20220039189A
KR20220039189A KR1020200121990A KR20200121990A KR20220039189A KR 20220039189 A KR20220039189 A KR 20220039189A KR 1020200121990 A KR1020200121990 A KR 1020200121990A KR 20200121990 A KR20200121990 A KR 20200121990A KR 20220039189 A KR20220039189 A KR 20220039189A
Authority
KR
South Korea
Prior art keywords
lys
ile
asn
leu
ser
Prior art date
Application number
KR1020200121990A
Other languages
Korean (ko)
Inventor
박종진
이정혁
Original Assignee
(주)지플러스생명과학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)지플러스생명과학 filed Critical (주)지플러스생명과학
Priority to KR1020200121990A priority Critical patent/KR20220039189A/en
Priority to US18/027,598 priority patent/US20230374478A1/en
Priority to PCT/KR2021/012936 priority patent/WO2022065867A1/en
Publication of KR20220039189A publication Critical patent/KR20220039189A/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a genome editing composition including a novel CRISPR related protein and an enhancer, and a use thereof, wherein the composition has excellent indel efficiency compared to an existing CRISPR-Cas system, thereby being effectively used for genome editing.

Description

신규한 CRISPR 연관 단백질 및 인핸서를 포함하는 유전체 편집용 조성물, 및 이의 용도{Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof}Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof

본 발명은 신규한 CRISPR 연관 단백질 및 인핸서를 포함하는 유전체 편집용 조성물, 및 이의 용도에 관한 것이다.The present invention relates to a composition for genome editing comprising novel CRISPR-associated proteins and enhancers, and uses thereof.

유전체 편집(Genome Editing)이란 생명체의 유전정보를 자유롭게 교정하는 기술을 말한다. 생명과학분야의 진보와 유전체 서열 분석 기술의 발전을 통해 우리는 다양한 유전정보에 대해 폭넓게 이해할 수 있게 되었다. 예를 들어 동식물의 번식, 질병과 성장, 다양한 인간 유전질병을 일으키는 유전자 변이, 바이오연료의 생산 등을 위한 유전자에 대한 이해는 이미 확보된 상황이지만 이를 직접적으로 활용하여 생명체를 개선하고, 인간 질병을 치료하는 수준에까지 이르기 위해서는 그 이상의 기술 진보가 필수적이다.Genome editing refers to a technology that freely edits the genetic information of living things. Advances in the field of life sciences and advances in genome sequencing technology have enabled us to broadly understand a variety of genetic information. For example, understanding of genes for reproduction of plants and animals, disease and growth, genetic mutations that cause various human genetic diseases, and the production of biofuels have already been secured, but they can be directly used to improve life and prevent human diseases. In order to reach the level of treatment, further technological advances are essential.

유전체 편집 기술은 인간을 포함하여 동물, 식물, 미생물의 유전정보를 변화시켜 그 활용범위를 획기적으로 확장시킬 수 있다. 유전자 가위는 원하는 유전정보를 정확히 자를 수 있도록 설계되어 만들어지는 분자 도구로 유전체 편집 기술에서 핵심역할을 하고 있다. 유전자 서열분석 분야를 한 차원 발전시켰던 차세대시퀀싱(Next generation sequencing) 기술과 같이, 유전자 가위는 유전정보 활용의 속도와 그 범위를 확장시키고 새로운 산업 분야를 창출해 내는 핵심 기술이 되고 있다.Genome editing technology can dramatically expand the range of applications by changing the genetic information of animals, plants, and microorganisms, including humans. Genetic scissors are molecular tools designed and made to precisely cut desired genetic information and are playing a key role in genome editing technology. Like the next generation sequencing technology that advanced the field of gene sequencing to a new level, gene scissors are becoming a key technology that expands the speed and scope of the utilization of genetic information and creates a new industrial field.

지금까지 개발된 유전자 가위는 그 순서에 따라 3세대로 나눌 수 있다. 1세대 유전자 가위는 ZFN(Zinc Finger Nuclease), 2세대 유전자 가위는 TALEN(Transcription Activator-Like Effector Nuclease), 가장 최근에 연구된 CRISPR(Clustered regularly interspaced short palindromic repeat)-Cas(CRISPR-associated)9은 3세대 유전자 가위다.The gene scissors developed so far can be divided into three generations according to their order. The first-generation gene scissors are ZFN (Zinc Finger Nuclease), the second-generation gene scissors are TALEN (Transcription Activator-Like Effector Nuclease), and the most recently studied CRISPR (Clustered regularly interspaced short palindromic repeat)-Cas (CRISPR-associated)9 are 3rd generation gene scissors.

CRISPRs는 유전자 서열이 밝혀진 박테리아의 대략 40% 및 유전자 서열이 밝혀진 고세균의 90%의 유전체에서 발견되는 여러 짧은 직접 반복을 포함하는 좌위이다. Cas 단백질은 CRISPR RNA(crRNA) 및 trans-activating crRNA(tracrRNA)로 명명된 두 개의 RNA와 복합체를 형성했을 때, 활성 엔도뉴클레아제(endonuclease)를 형성하고, 그렇게 함으로써 파지 또는 플라스미드의 침입에서 외부 유전적 요소를 묵살하여 숙주 세포를 보호한다. crRNA는 전달에 외부 침입자로부터 점유되었던 숙주 유전체의 CRISPR 요소로부터 전사된다.CRISPRs are loci containing several short direct repeats found in the genome of approximately 40% of genetically sequenced bacteria and 90% of genetically sequenced archaea. When the Cas protein forms an active endonuclease when complexed with two RNAs termed CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA), they do so externally from invasion of the phage or plasmid. Protects host cells by ignoring genetic elements. The crRNA is transcribed from the CRISPR element of the host genome that has been occupied by a foreign invader for delivery.

이러한 CRISPR-Cas 시스템 유래의 RNA-가이드 뉴클레아제(RNA-guided nuclease)는 유전체를 편집할 수 있는 수단을 제공해준다. 특히, 단일 가이드 RNA(sgRNA)와 Cas 단백질을 이용하여 세포 및 기관의 유전체를 편집할 수 있는 기술과 관련된 연구들이 활발히 진행되어왔다. 최근, Cpf1(Cas12a) 단백질(Prevotella 및 Francisella 1 유래)이 CRISPR-Cas 시스템의 또 다른 뉴클레아제 단백질로서 보고되었고(B Zetsche, et al, 2015), 이에 따라 유전체 편집에 있어서 선택의 폭이 넓어졌다.The RNA-guided nuclease derived from the CRISPR-Cas system provides a means to edit the genome. In particular, studies related to a technology capable of editing the genome of cells and organs using single guide RNA (sgRNA) and Cas protein have been actively conducted. Recently, the Cpf1 (Cas12a) protein (derived from Prevotella and Francisella 1) was reported as another nuclease protein of the CRISPR-Cas system (B Zetsche, et al, 2015), thus broadening the choice in genome editing. lost.

다만, Cpf1 단백질 기반의 CRISPR-Cas 시스템 역시 종래 Cas9 단백질 기반 유전자 가위의 표적이탈(off-target) 문제를 여전히 나타낸다. 표적이탈 효과에 의한 비표적 DNA 절단은 전암유전자(proto-oncogene) 및 암억제유전자(tumor suppressor gene)와 같이 원치 않는 유전자에서 돌연변이를 야기할 수 있고, 전위(translocation), 결실(deletion), 및 역위(inversion)와 같은 유전체 재조합을 증가시킬 수 있어, 연구 분야 및 의학 분야 등에서 유전자 가위를 이용하는데 심각한 문제가 된다. 따라서, 최근 유전자 가위의 표적이탈을 감소시키기 위하여, 인델(indel) 효율이 우수한 유전자 가위를 개발하기 위한 연구가 수행되고 있으나, 전체 유전체 수준에서 표적이탈 효과 없이 표적 위치에만 특이적으로 작동하는 유전자 가위는 아직까지 보고된 바 없다.However, the CRISPR-Cas system based on the Cpf1 protein also still presents the off-target problem of the conventional Cas9 protein based gene scissors. Off-target DNA cleavage by off-target effects may cause mutations in unwanted genes such as proto-oncogenes and tumor suppressor genes, and may cause translocation, deletion, and Since it is possible to increase genomic recombination such as inversion, it becomes a serious problem in the use of gene scissors in research fields and medical fields. Therefore, recent studies have been conducted to develop gene scissors with excellent indel efficiency in order to reduce off-targeting of gene scissors. has not been reported yet.

이에, 본 발명자들은 인델 효율이 우수한 유전자 가위 시스템을 개발하기 위한 연구를 수행하여 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention by conducting research to develop a gene editing system with excellent indel efficiency.

대한민국 특허등록 제10-1828933호Korean Patent Registration No. 10-1828933

본 발명의 하나의 목적은 Cas12a 단백질 또는 이를 암호화하는 DNA; 표적 뉴클레오티드(target nucleotide) 서열과 혼성화 가능한 뉴클레오티드 서열을 포함하는 가이드 RNA 또는 이를 암호화하는 DNA; 및 인핸서(nhancer)를 포함하는 유전체 편집용 조성물을 제공하는 것이다.One object of the present invention is a Cas12a protein or DNA encoding the same; a guide RNA comprising a nucleotide sequence capable of hybridizing with a target nucleotide sequence or a DNA encoding the same; And to provide a composition for genome editing comprising an enhancer (enhancer).

본 발명의 다른 목적은 상기 유전체 편집용 조성물을 분리된 세포 또는 유기체에 도입하는 단계를 포함하는 유전체 편집 방법을 제공하는 것이다.Another object of the present invention is to provide a genome editing method comprising the step of introducing the composition for genome editing into an isolated cell or organism.

본 발명의 또 다른 목적은 상기 유전체 편집용 조성물을 분리된 세포 또는 인간을 제외한 유기체에 도입하는 단계를 포함하는 형질 전환체의 제조 방법을 제공하는 것이다.Another object of the present invention is to provide a method for producing a transformant comprising introducing the composition for genome editing into isolated cells or organisms other than humans.

본 발명의 일 양상은 Cas12a 단백질 또는 이를 암호화하는 DNA; 표적 뉴클레오티드(target nucleotide) 서열과 혼성화 가능한 뉴클레오티드 서열을 포함하는 가이드 RNA 또는 이를 암호화하는 DNA; 및 인핸서(nhancer)를 포함하는 유전체 편집용 조성물을 제공한다.One aspect of the present invention is a Cas12a protein or DNA encoding the same; a guide RNA comprising a nucleotide sequence capable of hybridizing with a target nucleotide sequence or a DNA encoding the same; And it provides a composition for genome editing comprising an enhancer (enhancer).

본 명세서에서 사용한 용어 "Cas12a"는 CRISPR 연관 단백질로써, Cpf1로도 지칭될 수 있는 type V CRISPR 시스템 단백질이다. Cas12a는 단일 단백질로써, crRNA과 결합하여 표적 유전자를 절단한다는 점은 type Ⅱ CRISPR 시스템 단백질인 Cas9와 유사하나, 그 작동 방식에서 차이가 있다. Cas12a 단백질은 하나의 crRNA로 작동하므로, Cas9의 경우와 같이 crRNA와 trans-activating crRNA(tracrRNA)를 동시에 사용하거나, 인위적으로 tracrRNA와 crRNA를 합친 single guide RNA(sgRNA)를 제작할 필요가 없다.As used herein, the term “Cas12a” is a CRISPR-associated protein, which is a type V CRISPR system protein, which may also be referred to as Cpf1. Cas12a is a single protein and is similar to Cas9, a type II CRISPR system protein, in that it binds to crRNA and cuts a target gene, but there is a difference in its operation method. Since Cas12a protein works as a single crRNA, there is no need to use crRNA and trans-activating crRNA (tracrRNA) at the same time as in Cas9 or to artificially create a single guide RNA (sgRNA) that combines tracrRNA and crRNA.

또한, Cas12a 시스템은 Cas9와 달리 PAM이 표적 서열의 5' 위치에 존재한다. 또한, Cas12a 시스템은 표적을 결정하는 guide RNA(gRNA)의 길이도 Cas9에 비해 짧다. 또한, Cas12a는 표적 DNA가 절단된 위치에 blunt-end가 아닌 5' overhang(sticky end)을 발생시키므로, 보다 정확하고 다양한 유전자 편집이 가능하다는 장점을 갖는다.In addition, in the Cas12a system, unlike Cas9, the PAM exists at the 5' position of the target sequence. In addition, in the Cas12a system, the length of the guide RNA (gRNA) that determines the target is also shorter than that of Cas9. In addition, since Cas12a generates a 5' overhang (sticky end) rather than a blunt-end at the position where the target DNA is cut, it has the advantage of enabling more accurate and various gene editing.

본 발명에서는 인핸서를 포함하는 type V CRISPR 시스템의 우수한 인델 효율이 확인되었다. 또한, 종래 AsCpf1 및 LbCpf1 대비 인델 효율이 낮아, type V CRISPR 시스템에 적용되기 어려운 것으로 알려진 mgCas12a-1의 C-말단에, 핵위치 신호인 myc-NLS를 반복연결한 mgCas12a-1-6XNLS를 인핸서와 함께 사용한 type V CRISPR 시스템의 현저히 우수한 인델 효율이 확인되었다. 따라서, 종래 type V CRISPR 시스템의 유전자 편집 효율을 개선하기 위해 엔도뉴클레아제로써, mgCas12a-1-6XNLS 및 인핸서가 유용하게 활용될 수 있음이 확인되었다.In the present invention, excellent indel efficiency of the type V CRISPR system including the enhancer was confirmed. In addition, the C-terminus of mgCas12a-1, which is known to be difficult to apply to the type V CRISPR system, due to its lower indel efficiency compared to conventional AsCpf1 and LbCpf1, and mgCas12a-1-6XNLS in which myc-NLS, a nuclear localization signal, is repeatedly linked with an enhancer Remarkably excellent indel efficiency of the type V CRISPR system used together was confirmed. Therefore, it was confirmed that mgCas12a-1-6XNLS and enhancer can be usefully utilized as endonucleases to improve the gene editing efficiency of the conventional type V CRISPR system.

본 발명에서 사용되는 용어, "가이드 RNA(gRNA)"는 표적 DNA에 상보적으로 결합할 수 있는 염기서열을 포함하는 RNA로, gRNA는 mgCas12a-1-6XNLS 단백질과 복합체를 형성할 수 있고, mgCas12a-1-6XNLS 단백질을 표적 DNA에 가져올 수 있는 단일 사슬 RNA를 말한다. 본 발명에서 가이드 RNA는 절단하고자 하는 어떠한 표적에 특이적이 되도록 제조될 수 있다.As used herein, the term "guide RNA (gRNA)" is an RNA comprising a nucleotide sequence capable of complementary binding to a target DNA, and gRNA can form a complex with mgCas12a-1-6XNLS protein, mgCas12a -1-6XNLS Refers to single-stranded RNA that can bring protein to target DNA. In the present invention, the guide RNA may be prepared to be specific for any target to be cut.

본 발명의 mgCas12a-1-6XNLS 단백질은 세포 내로 도입되기에 용이한 형태일 수 있다. 예를 들면, mgCas12a-1-6XNLS 단백질은 세포 투과 펩타이드 또는 단백질 전달 도메인(protein transduction domain)과 연결된 것일 수 있다. 상기 단백질 전달 도메인은 폴리-아르기닌 또는 HIV 유래의 TAT 단백질일 수 있으나, 이에 한정되는 것은 아니다.The mgCas12a-1-6XNLS protein of the present invention may be in a form that is easy to be introduced into a cell. For example, the mgCas12a-1-6XNLS protein may be linked to a cell penetrating peptide or a protein transduction domain. The protein transduction domain may be poly-arginine or HIV-derived TAT protein, but is not limited thereto.

가이드 RNA의 표적 DNA 서열의 상보적 사슬과 염기 쌍을 형성할 수 있는 서열의 길이는 17 내지 23bp, 18 내지 23bp, 19 내지 23bp, 보다 구체적으로 20 내지 23bp, 보다 더 구체적으로, 21 내지 23bp 일 수 있으나, 이에 한정되는 것은 아니다.The length of the sequence capable of forming a base pair with the complementary strand of the target DNA sequence of the guide RNA is 17 to 23 bp, 18 to 23 bp, 19 to 23 bp, more specifically 20 to 23 bp, even more specifically, 21 to 23 bp days However, the present invention is not limited thereto.

가이드 RNA에 의해 표적화되는 DNA 서열은 5'-말단 부위 상류에 3 내지 4 개의 추가적인 뉴클레오티드인 PAM(protospacer adjacent motif) 서열을 포함하며, 구체적으로 상기 PAM 서열은 5'-TTTG-3' 또는 5'-TTTA-3'인 것이 바람직하다.The DNA sequence targeted by the guide RNA includes a protospacer adjacent motif (PAM) sequence that is 3 to 4 additional nucleotides upstream of the 5'-end region, specifically, the PAM sequence is 5'-TTTG-3' or 5' -TTTA-3' is preferable.

mgCas12a-1-6XNLS 단백질은 분리 및/또는 정제에 유리한 태그와 연결될 수 있다. 예를 들어, His 태그, Flag 태그, S 태그 등과 같은 작은 펩타이드 태그, 또는 GST(Glutathione S-transferase) 태그, MBP(Maltose binding protein) 태그 등이 목적에 따라 사용될 수 있으나, 이에 한정되는 것은 아니다.The mgCas12a-1-6XNLS protein may be linked with a tag advantageous for isolation and/or purification. For example, a small peptide tag such as a His tag, a Flag tag, an S tag, or a Glutathione S-transferase (GST) tag, a Maltose binding protein (MBP) tag, etc. may be used depending on the purpose, but is not limited thereto.

본 발명의 CRISPR/mgCas12a-1-6XNLS 시스템은 가이드 RNA를 코딩하는 DNA 및 Cas 단백질을 코딩하는 핵산과 같은 분리된 핵산 자체로 이용될 수 있고, 또한 가이드 RNA, 또는/및 Cas 단백질을 발현하기 위한 발현 카세트를 포함하는 재조합 발현 벡터 형태로도 사용될 수 있다.The CRISPR/mgCas12a-1-6XNLS system of the present invention can be used as an isolated nucleic acid itself, such as a DNA encoding a guide RNA and a nucleic acid encoding a Cas protein, and also for expressing the guide RNA, or/and a Cas protein. It can also be used in the form of a recombinant expression vector including an expression cassette.

본 발명에서 사용되는 용어, "재조합 발현벡터"는 목적한 코딩 서열과, 특정 숙주 생물에서 작동가능하게 연결된 코딩 서열을 발현하는데 필수적인 적정 핵산 서열을 포함하는 재조합 DNA 분자를 의미한다. 진핵세포에서 이용 가능한 프로모터, 인핸서, 종결신호 및 폴리아데닐레이션 신호는 공지되어 있다.As used herein, the term "recombinant expression vector" refers to a recombinant DNA molecule comprising a desired coding sequence and an appropriate nucleic acid sequence essential for expressing a coding sequence operably linked in a specific host organism. Promoters, enhancers, termination signals and polyadenylation signals available in eukaryotes are known.

본 발명에서 사용되는 용어, "작동가능하게 연결된"은 유전자 발현 조절 서열과 다른 뉴클레오티드 서열사이의 기능적인 결합을 의미한다. 상기 유전자 발현 조절 서열은 복제원점(replication origin), 프로모터 및 전사 종결 서열(terminator) 등으로 이루어진 군으로부터 선택되는 1종 이상일 수 있다. 전사 종결 서열은 폴리아데닐화 서열(pA)일 수 있으며, 복제 원점은 f1 복제원점, SV40 복제원점, pMB1 복제원점, 아데노 복제원점, AAV 복제원점 또는 BBV 복제원점 등일 수 있으나, 이에 한정되는 것은 아니다.As used herein, the term “operably linked” refers to a functional linkage between a gene expression control sequence and another nucleotide sequence. The gene expression control sequence may be at least one selected from the group consisting of an origin of replication, a promoter, and a terminator. The transcription termination sequence may be a polyadenylation sequence (pA), and the origin of replication may be an f1 origin of replication, an SV40 origin of replication, a pMB1 origin of replication, an adeno origin of replication, an AAV origin of replication, or a BBV origin of replication, but is not limited thereto. .

본 발명에서 사용되는 용어, "프로모터"는 구조 유전자로부터의 DNA 업스트림의 영역을 의미하며, 전사를 개시하기 위하여 RNA 폴리머라아제가 결합하는 DNA 분자를 말한다.As used herein, the term "promoter" refers to a region upstream of DNA from a structural gene, and refers to a DNA molecule to which RNA polymerase binds to initiate transcription.

본 발명의 일 구체예에 따른 프로모터는 특정 유전자의 전사 개시를 조절하는 전사 조절 서열 중 하나로, 약 100bp 내지 약 2500bp 길이의 폴리뉴클레오티드 단편일 수 있다. 프로모터는 세포, 예를 들어, 진핵 세포(예컨대, 식물 세포, 또는 동물 세포(예를 들어, 인간, 마우스 등의 포유류 세포 등) 등)에서 전사 개시를 조절할 수 있으면, 제한 없이 사용 가능하다. 예를 들어, 프로모터는 CMV 프로모터(cytomegalovirus promoter(예를 들어, 인간 또는 마우스 CMV immediate-early 프로모터), U6 프로모터, EF1-alpha(elongation factor 1-a) 프로모터, EF1-alpha short(EFS) 프로모터, SV40 프로모터, 아데노바이러스 프로모터(major late promoter), pL λ 프로모터, trp 프로모터, lac 프로모터, tac 프로모터, T7 프로모터, 백시니아 바이러스 7.5K 프로모터, HSV의 tk 프로모터, SV40E1 프로모터, 호흡기 세포융합 바이러스(Respiratory syncytial virus; RSV) 프로모터, 메탈로티오닌 프로모터(metallothionin promoter), β-액틴 프로모터, 유비퀴틴 C 프로모터, 인간 IL-2(human interleukin-2) 유전자 프로모터, 인간 림포톡신(human lymphotoxin) 유전자 프로모터 및 인간 GM-CSF(human granulocyte-macrophage colony stimulating factor) 유전자 프로모터로 이루어진 군으로부터 선택되는 것일 수 있으나, 이에 한정되는 것은 아니다. The promoter according to one embodiment of the present invention is one of the transcription control sequences that regulate the transcription initiation of a specific gene, and may be a polynucleotide fragment of about 100 bp to about 2500 bp in length. The promoter can be used without limitation, as long as it can regulate transcription initiation in a cell, for example, a eukaryotic cell (eg, a plant cell, or an animal cell (eg, a mammalian cell such as a human, a mouse, etc.)). For example, the promoter may be a CMV promoter (cytomegalovirus promoter (eg human or mouse CMV immediate-early promoter), U6 promoter, elongation factor 1-a (EF1-alpha) promoter, EF1-alpha short (EFS) promoter, SV40 promoter, adenovirus promoter (major late promoter), pL λ promoter, trp promoter, lac promoter, tac promoter, T7 promoter, vaccinia virus 7.5K promoter, HSV tk promoter, SV40E1 promoter, respiratory syncytial virus; RSV promoter, metallotionin promoter, β-actin promoter, ubiquitin C promoter, human interleukin-2 (IL-2) gene promoter, human lymphotoxin gene promoter, and human GM -CSF (human granulocyte-macrophage colony stimulating factor) may be selected from the group consisting of gene promoters, but is not limited thereto.

본 발명의 일 구체예에 따른 재조합 발현벡터는 플라스미드 벡터, 코즈미드 벡터 및 박테리오파아지 벡터, 아데노바이러스 벡터, 레트로바이러스 벡터 및 아데노-연관 바이러스 벡터와 같은 바이러스 벡터로 이루어진 군으로부터 선택되는 것일 수 있다. 재조합 발현벡터로 사용될 수 있는 벡터는 당업계에서 사용되는 플라스미드(예를 들어, pcDNA 시리즈, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX 시리즈, pET 시리즈, pUC19 등), 파지(예를 들어, λgt4λB, λ-Charon, λΔz1, M13 등) 또는 바이러스 벡터(예를 들어, 아데노-연관 바이러스(AAV) 벡터 등) 등을 기본으로 하여 제작될 수 있으나, 이에 한정되는 것은 아니다.The recombinant expression vector according to an embodiment of the present invention may be selected from the group consisting of viral vectors such as plasmid vectors, cosmid vectors and bacteriophage vectors, adenoviral vectors, retroviral vectors and adeno-associated viral vectors. Vectors that can be used as recombinant expression vectors include plasmids used in the art (eg, pcDNA series, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1). , pHV14, pGEX series, pET series, pUC19, etc.), phage (eg, λgt4λB, λ-Charon, λΔz1, M13, etc.) or viral vectors (eg, adeno-associated virus (AAV) vectors, etc.) It may be manufactured based on, but is not limited thereto.

본 발명의 재조합 발현벡터는 하나 이상의 선택성 마커를 더 포함할 수 있다. 상기 마커는 통상적으로 화학적인 방법으로 선택될 수 있는 특성을 갖는 핵산 서열로, 형질주입된 세포를 비형질주입 세포로부터 구별할 수 있는 모든 유전자가 이에 해당된다. 예를 들어, 글리포세이트(glyphosate), 글루포시네이트암모늄(glufosinate ammonium) 또는 포스피노트리신(phosphinothricin)과 같은 제초제 저항성 유전자, 암피실린(ampicillin), 카나마이신(kanamycin), G418, 블레오마이신(Bleomycin), 하이그로마이신(hygromycin), 클로람페니콜(chloramphenicol)과 같은 항생제 내성 유전자일 수 있으나, 이에 한정되는 것은 아니다.The recombinant expression vector of the present invention may further include one or more selectable markers. The marker is a nucleic acid sequence having characteristics that can be selected by conventional chemical methods, and includes all genes capable of distinguishing a transfected cell from a non-transfected cell. For example, herbicide resistance genes such as glyphosate, glufosinate ammonium or phosphinothricin, ampicillin, kanamycin, G418, Bleomycin , hygromycin (hygromycin), may be an antibiotic resistance gene such as chloramphenicol (chloramphenicol), but is not limited thereto.

본 발명의 재조합 발현벡터의 제작은 당해 기술 분야에서 잘 알려진 유전자 재조합 기술을 이용하여 제조할 수 있으며, 부위-특이적 DNA 절단 및 연결은 당해 기술 분야에서 일반적으로 알려진 효소 등을 사용하여 수행될 수 있다.The production of the recombinant expression vector of the present invention can be prepared using a genetic recombination technique well known in the art, and site-specific DNA cleavage and ligation can be performed using enzymes generally known in the art. there is.

본 발명의 일 구체예에 따르면, 상기 Cas12a 단백질은 서열번호 1의 아미노산 서열로 이루어진 단백질; 및 상기 단백질의 C-말단에 서열번호 4로 이루어진 myc-NLS(nuclear localization sequences)가 연결된 Cas12a 단백질인 것일 수 있다.According to one embodiment of the present invention, the Cas12a protein is a protein consisting of the amino acid sequence of SEQ ID NO: 1; and myc-NLS (nuclear localization sequences) of SEQ ID NO: 4 linked to the C-terminus of the protein may be a Cas12a protein.

본 발명의 일 구체예에 따르면, 상기 연결은 Gly-Gly-Ser 아미노산 서열에 의한 것일 수 있다.According to one embodiment of the present invention, the linkage may be by a Gly-Gly-Ser amino acid sequence.

myc-NLS는 Gly-Gly-Ser 아미노산 서열에 의해 mgCas12a-1의 C-말단에 연결되는 것이 바람직하다.Myc-NLS is preferably linked to the C-terminus of mgCas12a-1 by a Gly-Gly-Ser amino acid sequence.

본 발명의 일 구체예에 따르면, 상기 myc-NLS는 2 내지 10개가 반복연결된 것일 수 있다.According to one embodiment of the present invention, 2 to 10 of the myc-NLS may be repeatedly linked.

본 발명의 일 구체예에 따르면, 상기 myc-NLS는 6개가 반복연결된 것일 수 있다.According to one embodiment of the present invention, the myc-NLS may be six repeats.

본 발명의 일 구체예에 따르면, 상기 myc-NLS는 각각 Gly-Gly-Ser 아미노산 서열로 연결된 것일 수 있다.According to one embodiment of the present invention, the myc-NLS may be linked by a Gly-Gly-Ser amino acid sequence, respectively.

mgCas12a-1의 C-말단에 연결되는 myc-NLS는 복수개가 반복연결된 것일 수 있고, 바람직하게는 2 내지 10개가 반복연결된 것일 수 있으며, 가장 바람직하게는 6개가 반복연결된 것일 수 있다. myc-NLS는 복수개의 mgCas12a-1 C-말단 반복연결에 의하여, mgCas12a-1의 유전자 편집 효율이 현저히 개선될 수 있으며, myc-NLS는 Gly-Gly-Ser 아미노산 서열에 의해 서로 연결될 수 있다.A plurality of myc-NLS linked to the C-terminus of mgCas12a-1 may be repeat-linked, preferably 2 to 10 repeat-linked ones, and most preferably 6 repeat-linked ones. In myc-NLS, gene editing efficiency of mgCas12a-1 can be remarkably improved by a plurality of mgCas12a-1 C-terminal repeats, and myc-NLS can be linked to each other by a Gly-Gly-Ser amino acid sequence.

본 발명의 일 구체예에 따르면, 상기 서열번호 1의 아미노산 서열 중 169번째 위치의 라이신(Lys)이 아르기닌(Arg)으로 치환된 것일 수 있다.According to one embodiment of the present invention, lysine (Lys) at position 169 in the amino acid sequence of SEQ ID NO: 1 may be substituted with arginine (Arg).

본 발명의 일 구체예에 따르면, 상기 서열번호 1의 아미노산 서열 중 529번째 위치의 아스파르트산(Asp)이 아르기닌(Arg)으로 치환된 것일 수 있다.According to one embodiment of the present invention, aspartic acid (Asp) at position 529 in the amino acid sequence of SEQ ID NO: 1 may be substituted with arginine (Arg).

특히, 본 발명의 mgCas12a-1-6XNLS의 아미노산 서열 중 169번째 위치의 라이신(Lys)이 아르기닌(Arg)으로 치환 및 529번째 위치의 아스파르트산(Asp)이 아르기닌(Arg)으로 치환에 의해 최적화된 opmgCas12a-1-6XNLS에 의하여 효과적인 유전자 편집이 이루어질 수 있다.In particular, in the amino acid sequence of mgCas12a-1-6XNLS of the present invention, lysine (Lys) at position 169 is substituted with arginine (Arg) and aspartic acid (Asp) at position 529 is optimized by substitution with arginine (Arg) Efficient gene editing can be achieved by opmgCas12a-1-6XNLS.

본 발명의 일 구체예에 따르면, 상기 Cas12a 단백질은 서열번호 19의 아미노산 서열로 이루어진 것일 수 있다.According to one embodiment of the present invention, the Cas12a protein may be composed of the amino acid sequence of SEQ ID NO: 19.

본 발명의 다른 양상은 상기 유전체 편집용 조성물을 분리된 세포 또는 유기체에 도입하는 단계를 포함하는 유전체 편집 방법을 제공한다.Another aspect of the present invention provides a genome editing method comprising the step of introducing the composition for genome editing into an isolated cell or organism.

본 발명의 또 다른 양상은 상기 유전체 편집용 조성물을 분리된 세포 또는 인간을 제외한 유기체에 도입하는 단계를 포함하는 형질 전환체의 제조 방법을 제공한다.Another aspect of the present invention provides a method for producing a transformant comprising introducing the composition for genome editing into isolated cells or organisms other than humans.

본 발명의 유전체 편집용 조성물은 핵산 분자를 유기체, 세포, 조직 또는 기관에 도입하는 당 분야에서 공지된 방법에 의해 세포 또는 유기체에 도입될 수 있으며, 당 분야에서 공지된 바와 같이 숙주 세포에 따라 적합한 표준 기술을 선택하여 수행할 수 있다. 이런 방법에는 예를 들어, 전기천공법(electroporation), 인산칼슘(CaPO4) 침전, 염화칼슘(CaCl2) 침전, 미세주입법(microinjection), 폴리에틸렌글리콜(PEG)법, DEAE-덱스트란법, 양이온성 리포좀법, 및 초산 리튬-DMSO법 등이 포함될 수 있으나, 이에 한정되는 것은 아니다.The composition for genome editing of the present invention may be introduced into a cell or organism by a method known in the art for introducing a nucleic acid molecule into an organism, cell, tissue or organ, and as is known in the art, it may be suitable depending on the host cell. This can be done by selecting standard techniques. Such methods include, for example, electroporation, calcium phosphate (CaPO 4 ) precipitation, calcium chloride (CaCl 2 ) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic The liposome method and the lithium acetate-DMSO method may be included, but are not limited thereto.

신규한 CRISPR 연관 단백질 및 인핸서를 포함하는 유전체 편집용 조성물, 및 이의 용도에 따르면, 기존의 CRISPR-Cas 시스템 대비 인델 효율이 우수하므로, 유전자 편집에 효과적으로 활용될 수 있다.According to a composition for genome editing comprising a novel CRISPR-related protein and enhancer, and its use, indel efficiency is excellent compared to the existing CRISPR-Cas system, and thus can be effectively utilized for gene editing.

도 1은 pET28a-His-opmgCas12a-1-6XNLS-His 재조합 발현 벡터의 구조를 나타낸 그림이다.
도 2는 SDS-PAGE에 의하여 opmgCas12a-1-6XNLS 단백질의 최적 발현 조건이 확인된 사진이다.
도 3은 His 컬럼을 사용하여 opmgCas12a-1-6XNLS를 확인한 FPLC 크로마토그래피 결과를 나타낸 그래프이다.
도 4는 탈염(desalting) 컬럼을 사용하여 opmgCas12a-1-6XNLS를 확인한 FPLC 크로마토그래피 결과를 나타낸 그래프이다.
도 5는 opmgCas12a-1-6XNLS 분획에 대한 SDS-PAGE의 쿠마시 염색 결과를 나타낸 사진이다.
도 6은 HEK293T에서 HPRT1 유전자에 대한 인핸서 유무에 따른 AsCas12a, mgCas12a1, opmgCas12a-1-6XNLS 및 mgCas12a1-GFP의 녹아웃(knockout) 효율을 비교한 사진이다.
도 7은 HEK293T에서 HPRT1 유전자에 대한 인핸서 유무에 따른 AsCas12a, mgCas12a1, opmgCas12a-1-6XNLS 및 mgCas12a1-GFP의 녹아웃(knockout) 효율을 비교한 그래프이다.1 is a diagram showing the structure of a pET28a-His-opmgCas12a-1-6XNLS-His recombinant expression vector.
2 is a photograph confirming the optimal expression conditions of the opmgCas12a-1-6XNLS protein by SDS-PAGE.
3 is a graph showing the results of FPLC chromatography confirming opmgCas12a-1-6XNLS using a His column.
4 is a graph showing the results of FPLC chromatography confirming opmgCas12a-1-6XNLS using a desalting column.
5 is a photograph showing the Coomassie staining result of SDS-PAGE for the opmgCas12a-1-6XNLS fraction.
6 is a photograph comparing the knockout efficiency of AsCas12a, mgCas12a1, opmgCas12a-1-6XNLS and mgCas12a1-GFP according to the presence or absence of an enhancer for the HPRT1 gene in HEK293T.
7 is a graph comparing the knockout efficiency of AsCas12a, mgCas12a1, opmgCas12a-1-6XNLS and mgCas12a1-GFP according to the presence or absence of an enhancer for the HPRT1 gene in HEK293T.

이하 본 발명을 하나 이상의 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through one or more embodiments. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

실시예 1. 유전자 편집 효율이 증가된 mgCas12a-1 변이체 재조합 벡터 제작Example 1. Construction of mgCas12a-1 mutant recombinant vector with increased gene editing efficiency

1-1. pET28a-His-mgCas12a-1-6XNLS-His 재조합 벡터1-1. pET28a-His-mgCas12a-1-6XNLS-His recombinant vector

서열번호 2의 염기서열에 의해 암호화되는 서열번호 1의 아미노산 서열을 갖는 단백질(mgCas12a-1)의 유전자 편집 효율을 증가시키기 위하여, mgCas12a-1의 C-말단에 표 1의 myc-NLS(nuclear localization sequences)를 6번 반복하여 추가한 단백질 변이체(mgCas12a-1-6XNLS) 재조합 벡터를 제작하였다.In order to increase the gene editing efficiency of the protein (mgCas12a-1) having the amino acid sequence of SEQ ID NO: 1 encoded by the nucleotide sequence of SEQ ID NO: 2, myc-NLS (nuclear localization in Table 1) at the C-terminus of mgCas12a-1 sequences) were repeated 6 times to construct a recombinant vector of protein variants (mgCas12a-1-6XNLS) added.

명칭designation 구분division 서열order 서열번호SEQ ID NO: myc-NLSmyc-NLS 염기서열(5'→3')Base sequence (5'→3') ccggcagccaagagagtcaaactcgacccggcagccaagagagtcaaactcgac 서열번호 3SEQ ID NO: 3 아미노산서열(N→C)Amino acid sequence (N→C) PAAKRVKLDPAAKRVKLD 서열번호 4SEQ ID NO: 4

구체적으로, 표 2의 Core region(130bp)을 프라이머 형태로 주문하여 어닐링(annealing)한 후, 표 3의 신장(extension) 프라이머를 사용하여 PCR 증폭함으로써, 인서트(Insert)를 준비하였다. Specifically, the core region (130bp) of Table 2 was ordered in the form of a primer and annealed, and then PCR amplified using the extension primer of Table 3 to prepare an insert.

명칭designation 염기서열(5'→3')Base sequence (5'→3') 서열번호SEQ ID NO: Core regionCore region agccaagagagtcaaactcgacggcggctccccagcggcaaaaagggtgaaactagacgggggtagccccgccgcgaagcgtgtaaagctggatggaggatcgcctgcggctaagcgagtcaaattagacagccaagagagtcaaactcgacggcggctccccagcggcaaaaagggtgaaactagacgggggtagccccgccgcgaagcgtgtaaagctggatggaggatcgcctgcggctaagcgagtcaaattagac 서열번호 5SEQ ID NO: 5

프라이머primer 프라이머 염기서열(5'→3')Primer sequence (5'→3') 서열번호SEQ ID NO: extension primerextension primer forwardforward ttgacttcattcaaaataagcggtatctgggcggctcccctgctgctaaacgtgttaagcttgatgggggtagcccggcagccaagagagtcaaactcgttgacttcattcaaaataagcggtatctgggcggctcccctgctgctaaacgtgttaagcttgatgggggtagcccggcagccaagagagtcaaactcg 서열번호 6SEQ ID NO: 6 reversereverse agccggatctcagtggtggtggtggtggtggctgccgctagcatccaatttgacgcgctttgcagccggtgacccaccgtctaatttgactcgcttagccagccggatctcagtggtggtggtggtggtggctgccgctagcatccaatttgacgcgctttgcagccggtgacccaccgtctaatttgactcgcttagcc 서열번호 7SEQ ID NO: 7

한편, 종래 사용되고 있는 pET28a-6XHis-mgCas12a-1 플라스미드를 NotI 및 SalI으로 이중 절단(double cut)하여 벡터를 준비하였다. 이후, 깁슨 어셈블리(Gibson assembly)를 수행하여, 벡터에 인서트를 클로닝한 결과, 3개의 콜로니(colony)에서 pET28a-His-mgCas12a-1-6XNLS-His 구조(construction)가 제작된 것으로 확인되었다. mgCas12a-1-6XNLS 단백질은 서열번호 9의 염기서열로 코딩되는 서열번호 8의 아미노산 서열을 갖는다Meanwhile, the conventionally used pET28a-6XHis-mgCas12a-1 plasmid was double cut with NotI and SalI to prepare a vector. Thereafter, Gibson assembly was performed, and as a result of cloning the insert into the vector, it was confirmed that the pET28a-His-mgCas12a-1-6XNLS-His structure was produced in three colonies. mgCas12a-1-6XNLS protein has the amino acid sequence of SEQ ID NO: 8 encoded by the nucleotide sequence of SEQ ID NO: 9

1-2. pET28a-His-opmgCas12a-1-6XNLS-His 재조합 벡터1-2. pET28a-His-opmgCas12a-1-6XNLS-His recombinant vector

실시예 1-1의 mgCas12a-1-6XNLS의 재조합 벡터에서, 점돌연변이(point mutation)에 의해 코돈 최적화된 opmgCas12a-1-6XNLS 재조합 벡터를 제작하였다.In the mgCas12a-1-6XNLS recombinant vector of Example 1-1, a codon-optimized opmgCas12a-1-6XNLS recombinant vector was prepared by point mutation.

구체적으로, 인서트간의 상동성 재조합(homologous recombination, HR) 부위에 점돌연변이(K169R 및 D529R)가 생성되도록 디자인하였다(도 1). 그 후, PCR 증폭한 후, DpnI 처리 및 PCR 산물을 수득하여 3가지의 인서트를 각각 준비하였다.Specifically, it was designed to generate point mutations (K169R and D529R) at the site of homologous recombination (HR) between inserts ( FIG. 1 ). Then, after PCR amplification, DpnI treatment and PCR products were obtained to prepare three inserts, respectively.

인서트 염기서열(5'→3')Insert sequence (5'→3') Forward primerforward primer Reverse primerReverse primer 1One 서열번호 10SEQ ID NO: 10 서열번호 11SEQ ID NO: 11 서열번호 12SEQ ID NO: 12 gcgccaaattgattagtgacatcctgccggaattcgttattcacaataacaattactctgctagcgagaaggaagagaaaacccaagtcataaagctcttttcccggttcgccacttcatttaaagattatttccgcaaccgcgcaaattgctttagcgccgacgcgccaaattgattagtgacatcctgccggaattcgttattcacaataacaattactctgctagcgagaaggaagagaaaacccaagtcataaagctctttttcccggttcgccacttcatttaaagattattttccgcaaccgcgcaaattgctttagcgccgac gcgccaaattgattagtgacatcctgccggaattcgttattcacaataacaatgcgccaaattgattagtgacatcctgccggaattcgttattcacaataacaat gtcggcgctaaagcaatttgcgcggttgcggaaataatctttaaatgaagtggcgtcggcgctaaagcaatttgcgcggttgcggaaataatctttaaatgaagtggc 22 서열번호 13SEQ ID NO: 13 서열번호 14SEQ ID NO: 14 서열번호 15SEQ ID NO: 15 cgcaaccgcgcaaattgctttagcgccgacgatatcagttctagctcctgtcatcggattgtgaacgacaatgctgaaatcttcttttcaaacgcccttgtataccgccggattgtgaaaaatctgagcaacgatgacataaataagatcagtggagatattaaagactctttgaaggagatgagcctggaagagatctattcctacgaaaaatatggggagttcattacccaggaaggcatatcattttacaacgatatctgcggtaaggttaatagcttcatgaacctctattgtcagaaaaataaggagaacaaaaatctttacaagctgcgcaaattgcacaagcaaattctgtgcatcgcagacacaagttatgaagtcccttacaaatttgagtctgatgaagaggtgtatcagagcgtaaacggcttcctcgacaatatttcctcaaagcatatagtggaacggcttcgcaaaatcggagataactacaatgggtataacctggacaagatttacatcgttagcaaattttatgagagtgtctctcagaagacctaccgggattgggaaactattaataccgccttggagatacactataacaatatcctgcccggcaacggtaaaagcaaggctgacaaagtgaagaaagccgtaaagaatgatctccaaaaatccattacagaaatcaacgagcttgtgtcaaattacaagctgtgtccggacgataacattaaagcagaaacctatatacatgagatcagccacattttgaataacttcgaagcccaggagctgaagtacaatccagaaatccatctcgttgagagtgaacttaaagcttctgagctgaagaacgtcttggacgtgattatgaatgcctttcactggtgcagcgtattcatgactgaagagctggtggataaagacaacaatttttatgcagaactcgaggaaatatacgatgagatctataccgttatttccctttacaacctggtccgcaattatgtgacacagaagccctactcaaccaaaaagatcaaattgaacttcggcattccgactctggcccgccgcaaccgcgcaaattgctttagcgccgacgatatcagttctagctcctgtcatcggattgtgaacgacaatgctgaaatcttcttttcaaacgcccttgtataccgccggattgtgaaaaatctgagcaacgatgacataaataagatcagtggagatattaaagactctttgaaggagatgagcctggaagagatctattcctacgaaaaatatggggagttcattacccaggaaggcatatcattttacaacgatatctgcggtaaggttaatagcttcatgaacctctattgtcagaaaaataaggagaacaaaaatctttacaagctgcgcaaattgcacaagcaaattctgtgcatcgcagacacaagttatgaagtcccttacaaatttgagtctgatgaagaggtgtatcagagcgtaaacggcttcctcgacaatatttcctcaaagcatatagtggaacggcttcgcaaaatcggagataactacaatgggtataacctggacaagatttacatcgttagcaaattttatgagagtgtctctcagaagacctaccgggattgggaaactattaataccgccttggagatacactataacaatatcctgcccggcaacggtaaaagcaaggctgacaaagtgaagaaagccgtaaagaatgatctccaaaaatccattacagaaatcaacgagcttgtgtcaaattacaagctgtgtccggacgataacattaaagcagaaacctatatacatgagatcagccacattttgaataacttcgaagcccaggagctgaagtacaatccagaaatccatctcgttgagagtgaacttaaagcttctgagctgaagaacgtcttggacgtgattatgaatgcctttcactggtgcagcgtattcatgactgaagagctggtggataaagacaacaatttttatgcagaactcgaggaaatatacgatgagatctataccgttatttccctttaca acctggtccgcaattatgtgacacagaagccctactcaaccaaaaagatcaaattgaacttcggcattccgactctggcccgc cgcaaccgcgcaaattgctttagcgccgaccgcaaccgcgcaaattgctttagcgccgac gcgggccagagtcggaatgccgaagttcaagcgggccagagtcggaatgccgaagttcaa 33 서열번호 16SEQ ID NO: 16 서열번호 17SEQ ID NO: 17 서열번호 18SEQ ID NO: 18 ttgaacttcggcattccgactctggcccgcggatggagcaagagtaaagaatattctaataacgctataatcctcatgcgggataatctttactatctggggatttttaacgccaagaataaacctgacaagaaaatcattgagggcaacaccagcgaaaataagggtgattacaaaaagatgatatataacttgctgcccggcccgaataaaatgatcccaaaggtattcctctcctcaaaaacaggagtggagacctacaagcccagcgcatatattctttgaacttcggcattccgactctggcccgcggatggagcaagagtaaagaatattctaataacgctataatcctcatgcgggataatctttactatctggggatttttaacgccaagaataaacctgacaagaaaatcattgagggcaacaccagcgaaaataagggtgattacaaaaagatgatatataacttgctgcccggcccgaataaaatgatcccaaaggtattcctctcctcaaaaacaggagtggagacctacaagcccagcgcatatattct ttgaacttcggcattccgactctggcccgcggatggagcaagagtaaagattgaacttcggcattccgactctggcccgcggatggagcaagagtaaaga agaatatatgcgctgggcttgtaggtctccactcctgtttttgaggagagagaatatatgcgctgggcttgtaggtctccactcctgttttttgaggagag

한편, 실시예 1-1의 pET28a-His-mgCas12a-1-6XNLS-His 벡터를 EcorI과 BsaI을 사용하여 이중 절단하여 벡터를 준비하였다. 이후, 깁슨 어셈블리를 수행하여 벡터에 인서트를 클로닝함으로써, opmgCas12a-1이 클로닝된 pET28a-His-opmgCas12a-1-6XNLS-His 재조합 벡터를 제작하였다. opmgCas12a-1-6XNLS 단백질은 서열번호 20의 염기서열로 코딩되는 서열번호 19의 아미노산 서열을 갖는다.Meanwhile, the pET28a-His-mgCas12a-1-6XNLS-His vector of Example 1-1 was double digested using EcoI and BsaI to prepare a vector. Thereafter, by performing Gibson assembly and cloning the insert into the vector, a pET28a-His-opmgCas12a-1-6XNLS-His recombinant vector in which opmgCas12a-1 was cloned was constructed. The opmgCas12a-1-6XNLS protein has the amino acid sequence of SEQ ID NO: 19 encoded by the nucleotide sequence of SEQ ID NO: 20.

실시예 2. opmgCas12a-1-6XNLS 단백질 발현 최적조건 확인Example 2. Confirmation of optimal conditions for expression of opmgCas12a-1-6XNLS protein

2-1. 형질전환2-1. transformation

실시예 1-2에서 제작한 opmgCas12a-1-6XNLS 발현 재조합 벡터를 컴피턴트 세포(competent cell)인 Rosetta(DE3) 또는 Rosetta2(DE3)pLysS에 각각에 각각 형질전환하였다.The recombinant vector expressing opmgCas12a-1-6XNLS prepared in Example 1-2 was transformed into competent cells, Rosetta(DE3) or Rosetta2(DE3)pLysS, respectively.

구체적으로, Rosetta(DE3) 또는 Rosetta2(DE3)pLysS 100㎕에 실시예 1-2의 재조합 벡터 1㎕를 넣은 후 얼음상에서 30분 동안 반응시켰다. 그 후, 42℃에서 45초간 열 충격(heat shock)을 가한 후 재빨리 얼음으로 옮겨 2분 동안 반응시켰다. LB 배지 1㎖을 넣은 후, 37℃에서 1시간 동안 진탕배양(shaking incubation)한 다음, 13,000rpm에서 3분간 원심분리하여 세포를 침전시키고, 상층액 100㎕를 남긴 후 재현탁(resuspension)하여, 카나마이신이 함유된 LB 플레이트에 스프레딩(spreading)한 다음, 37℃에서 밤새 배양하여 형질전환하였다.Specifically, 1 μl of the recombinant vector of Example 1-2 was added to 100 μl of Rosetta (DE3) or Rosetta2 (DE3) pLysS, and then reacted on ice for 30 minutes. Thereafter, heat shock was applied at 42° C. for 45 seconds, and then quickly transferred to ice and reacted for 2 minutes. After adding 1 ml of LB medium, shaking incubation at 37° C. for 1 hour, centrifugation at 13,000 rpm for 3 minutes to precipitate cells, and resuspension after leaving 100 μl of the supernatant, After spreading on an LB plate containing kanamycin, it was transformed by culturing at 37° C. overnight.

2-2. 단백질 발현량 확인2-2. Confirmation of protein expression level

opmgCas12a-1-6XNLS 단백질 발현량을 확인하기 위하여, 실시예 2-1에서 형질전환된 Rosetta(DE3) 및 Rosetta2(DE3)pLysS의 발현 최적조건을 분석하였다.In order to confirm the expression level of opmgCas12a-1-6XNLS protein, optimal conditions for expression of Rosetta(DE3) and Rosetta2(DE3)pLysS transformed in Example 2-1 were analyzed.

구체적으로, 실시예 2-1에서 형질전환된 Rosetta(DE3) 또는 Rosetta2(DE3)pLysS를 하룻밤 동안 배양하고, 100㎎/㎖의 카나마이신 항생제가 추가된 500㎖의 액체 TB 배지에 5㎖를 접종한 후, 37℃ 배양기에서 0.6 OD600이 될 때까지 배양하였다. 0.5mM의 IPTG(Isopropyl β-D-1-thiogalactopyranoside)를 처리하여 opmgCas12a-1-6XNLS 단백질 발현을 유도한 후, 18℃ 또는 28℃에서 18시간 동안 배양하였다. 원심분리 후 수득한 세포를 10㎖의 용해 버퍼(20mM HEPES pH7.5, 100mM KCl, 20mM 이미다졸, 10% 글리세롤 및 EDTA-프리 프로테아제 인히비터 칵테일)와 혼합한 후, 초음파를 처리하여 세포를 분쇄하였다. 분쇄물을 6,000rpm에서 20분간 3회 원심분리한 후 0.22 마이크론 필터로 여과하였다. 이후, 니켈 컬럼(HisTrap FF 5㎖) 및 300mM 이미다졸 버퍼를 이용하여 세척 및 용출한 다음, SDS-PAGE 전기영동 및 쿠마시 염색(coomassie staning)을 수행하여 opmgCas12a-1-6XNLS 단백질을 확인하였다.Specifically, Rosetta (DE3) or Rosetta2 (DE3) pLysS transformed in Example 2-1 was cultured overnight, and 5 ml was inoculated into 500 ml of liquid TB medium containing 100 mg/ml of kanamycin antibiotic added. Then, it was cultured in an incubator at 37° C. until 0.6 OD 600 was reached. OpmgCas12a-1-6XNLS by treatment with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) After induction of protein expression, the cells were incubated at 18°C or 28°C for 18 hours. Cells obtained after centrifugation were mixed with 10 ml of lysis buffer (20 mM HEPES pH7.5, 100 mM KCl, 20 mM imidazole, 10% glycerol and EDTA-free protease inhibitor cocktail), followed by sonication to disrupt the cells. did. The pulverized product was centrifuged 3 times at 6,000 rpm for 20 minutes and then filtered through a 0.22 micron filter. Then, after washing and eluting using a nickel column (HisTrap FF 5㎖) and 300mM imidazole buffer, SDS-PAGE electrophoresis and Coomassie staning were performed to confirm the opmgCas12a-1-6XNLS protein.

그 결과, Rosetta2(DE3)pLysS를 사용한 18℃의 18시간 배양 조건이 opmgCas12a-1-6XNLS 단백질의 발현에 최적 조건인 것으로 확인되었다(도 2).As a result, it was confirmed that the 18-hour incubation condition at 18°C using Rosetta2(DE3)pLysS was the optimal condition for the expression of the opmgCas12a-1-6XNLS protein ( FIG. 2 ).

실시예 3. opmgCas12a-1-6XNLS 단백질 정제Example 3. opmgCas12a-1-6XNLS protein purification

실시예 2의 방법으로 세척 및 용출한 opmgCas12a-1-6XNLS 단백질을 크로마토그래피 방법으로 정제하였다.The opmgCas12a-1-6XNLS protein washed and eluted by the method of Example 2 was purified by chromatography.

구체적으로, opmgCas12a-1-6XNLS 단백질을 His 컬럼(column) 또는 탈염(desalting) 칼럼을 사용한 FPLC 크로마토그래피 방법으로 정제하였다. 투석 버퍼(20mM HEPES pH 7.5, 100mM KCl, 1mM DTT, 10% 글리세롤)로 하룻밤 동안 투석하고, 단백질 크기에 맞춰 선택적으로 여과 및 농축(Amicon Ultra Centrifugal Filter 100,000 MWCO)하여 opmgCas12a-1-6XNLS 단백질을 정제하였다. Specifically, the opmgCas12a-1-6XNLS protein was purified by FPLC chromatography using a His column or a desalting column. The opmgCas12a-1-6XNLS protein was purified by dialysis overnight in dialysis buffer (20 mM HEPES pH 7.5, 100 mM KCl, 1 mM DTT, 10% glycerol), followed by selective filtration and concentration according to protein size (Amicon Ultra Centrifugal Filter 100,000 MWCO). did.

SDS-PAGE 전기영동 및 쿠마시 염색을 수행하여 opmgCas12a-1-6XNLS 단백질의 정제 수율을 확인한 결과, 단백질 농도는 35.54㎎/㎖ 및 단백질 부피는 1.6㎖로써, 56.9㎎/ℓ의 opmgCas12a-1-6XNLS 단백질 정제 수율이 확인되었다(도 3 내지 도 5).As a result of confirming the purification yield of opmgCas12a-1-6XNLS protein by performing SDS-PAGE electrophoresis and Coomassie staining, the protein concentration was 35.54 mg/ml and the protein volume was 1.6 ml, which was 56.9 mg/L of opmgCas12a-1-6XNLS. Protein purification yield was confirmed ( FIGS. 3 to 5 ).

이후, 정제된 opmgCas12a-1-6XNLS 단백질은 브래드포드 정량법으로 농도를 측정하고, -80℃에서 보관하며 사용하였다.Thereafter, the purified opmgCas12a-1-6XNLS protein was The concentration was measured by the Bradford quantitative method, and it was stored at -80°C and used.

실시예 4. opmgCas12a-1-6XNLS의 향상된 유전자 편집 효율 확인Example 4. Confirmation of improved gene editing efficiency of opmgCas12a-1-6XNLS

4-1. HPRT1 유전자 편집을 위한 opmgCas12a-1-6XNLS를 포함한 RNP 제작4-1. Construction of RNPs with opmgCas12a-1-6XNLS for HPRT1 gene editing

HEK 293T 세포를 10% 태아 소혈청인 FBS와 P/S(penicillin-streptomycin)가 함유된 DMEM(Dulbecco Modified Eagle Medium)에서 37℃의 온도로 5% CO2 배양기에서 배양하였다. 126pmol의 opmgCas12a-1-6XNLS 단백질 5μM과 HPRT1을 표적화하는 160pmol의 crRNA(표 4) 6.4μM를 상온에서 20분간 배양하여 리보핵산단백질(RNP)을 제작하였다. 사용된 HPRT1의 crRNA 서열은 IDT(Integrated DNA Technologies)로부터 합성되었다.HEK 293T cells were cultured in DMEM (Dulbecco Modified Eagle Medium) containing 10% fetal bovine serum, FBS and penicillin-streptomycin (P/S), at a temperature of 37° C. and 5% CO 2 incubator. Ribonucleic acid protein (RNP) was prepared by incubating 126 pmol of opmgCas12a-1-6XNLS protein 5 μM and 160 pmol of crRNA targeting HPRT1 (Table 4) 6.4 μM at room temperature for 20 minutes. The crRNA sequence of HPRT1 used was synthesized from Integrated DNA Technologies (IDT).

유전자gene crRNA sequence(5'→3')crRNA sequence (5'→3') 서열번호SEQ ID NO: HPRT1HPRT1 GGTTAAAGATGGTTAAATGATGGTTAAAGATGGTTAAATGAT 서열번호 21SEQ ID NO: 21

HEK293T 세포 2×105개를 20㎕의 뉴클레오펙션(nucleofection) 시약과 혼합하고, 10㎕의 RNP, 또는 10㎕의 RNP 및 인핸서(최종농도 3μM)와 혼합한 다음, 4D-Nucleofector 기기(Lonza)를 사용하여 세포 내로 RNP를 전기천공(electroporation) 방법으로 도입하였다. 인핸서는 IDT사의 'Cpf1 electroporation enhancer, 10nmol(cat no. 1076301)'을 구입하여 사용하였다. 형질전환 48시간 후, PureLinkTM Genomic DNA Mini Kit(invitrogen)를 사용하여 세포로부터 게놈 DNA를 추출하였다.2×10 5 HEK293T cells were mixed with 20 μl of nucleofection reagent, mixed with 10 μl of RNP, or 10 μl of RNP and enhancer (final concentration 3 μM), followed by a 4D-Nucleofector device (Lonza) ) was used to introduce RNP into cells by an electroporation method. The enhancer was used by purchasing 'Cpf1 electroporation enhancer, 10 nmol (cat no. 1076301)' from IDT. 48 hours after transformation, genomic DNA was extracted from the cells using the PureLink ™ Genomic DNA Mini Kit (invitrogen).

4-2. 표적 부위에 대한 염기서열 분석4-2. Sequencing of the target site

실시예 4-1에서 추출한 게놈 DNA를 일루미나(Illumina)의 프로토콜에 따라 정제 및 시퀀싱 라이브러리를 제조하였으며, MiniSeq 장비를 이용하여 표적 부위에 대한 딥시퀀싱(deep sequencing) 분석을 진행하였다.The genomic DNA extracted in Example 4-1 was purified according to Illumina's protocol and a sequencing library was prepared, and deep sequencing analysis of the target site was performed using MiniSeq equipment.

그 결과, mgCas12a-1 대비 opmgCas12a-1-6XNLS의 HPRT1 유전자의 녹아웃 효율이 약 4배 우수한 것으로 나타났고, 종래 일반적으로 사용되는 AsCpf1보다도 녹아웃 효율이 약 2배 우수한 것으로 나타났으며, 인핸서 사용시 100%에 가까운 녹아웃 효율이 확인되어, opmgCas12a-1-6XNLS 단백질 및 인핸서에 의한 우수한 유전자 편집 효율이 확인되었다(도 6 및 도 7).As a result, the knockout efficiency of the HPRT1 gene of opmgCas12a-1-6XNLS was about 4 times superior to that of mgCas12a-1 compared to mgCas12a-1. Knockout efficiency close to was confirmed, and excellent gene editing efficiency by opmgCas12a-1-6XNLS protein and enhancer was confirmed ( FIGS. 6 and 7 ).

이제까지 본 발명에 대하여 그 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, the present invention has been looked at focusing on the embodiments thereof. Those of ordinary skill in the art to which the present invention pertains will understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments are to be considered in an illustrative rather than a restrictive sense. The scope of the present invention is indicated in the claims rather than the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.

<110> G+FLAS Life Sciences <120> Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof <130> SP20-0125KR <160> 21 <170> KoPatentIn 3.0 <210> 1 <211> 1330 <212> PRT <213> Artificial Sequence <220> <223> mgCas12a-1 <400> 1 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg 20 25 30 Gly Ser Met Asn Asn Gly Thr Asn Asn Phe Gln Asn Phe Ile Gly Ile 35 40 45 Ser Ser Leu Gln Lys Thr Leu Arg Asn Ala Leu Ile Pro Thr Glu Thr 50 55 60 Thr Gln Gln Phe Ile Val Lys Asn Gly Ile Ile Lys Glu Asp Glu Leu 65 70 75 80 Arg Gly Glu Asn Arg Gln Ile Leu Lys Asp Ile Met Asp Asp Tyr Tyr 85 90 95 Arg Gly Phe Ile Ser Glu Thr Leu Ser Ser Ile Asp Asp Ile Asp Trp 100 105 110 Thr Ser Leu Phe Glu Lys Met Glu Ile Gln Leu Lys Asn Gly Asp Asn 115 120 125 Lys Asp Thr Leu Ile Lys Glu Gln Ala Glu Lys Arg Lys Ala Ile Tyr 130 135 140 Lys Lys Phe Ala Asp Asp Asp Arg Phe Lys Asn Met Phe Ser Ala Lys 145 150 155 160 Leu Ile Ser Asp Ile Leu Pro Glu Phe Val Ile His Asn Asn Asn Tyr 165 170 175 Ser Ala Ser Glu Lys Glu Glu Lys Thr Gln Val Ile Lys Leu Phe Ser 180 185 190 Arg Phe Ala Thr Ser Phe Lys Asp Tyr Phe Lys Asn Arg Ala Asn Cys 195 200 205 Phe Ser Ala Asp Asp Ile Ser Ser Ser Ser Cys His Arg Ile Val Asn 210 215 220 Asp Asn Ala Glu Ile Phe Phe Ser Asn Ala Leu Val Tyr Arg Arg Ile 225 230 235 240 Val Lys Asn Leu Ser Asn Asp Asp Ile Asn Lys Ile Ser Gly Asp Ile 245 250 255 Lys Asp Ser Leu Lys Glu Met Ser Leu Glu Glu Ile Tyr Ser Tyr Glu 260 265 270 Lys Tyr Gly Glu Phe Ile Thr Gln Glu Gly Ile Ser Phe Tyr Asn Asp 275 280 285 Ile Cys Gly Lys Val Asn Ser Phe Met Asn Leu Tyr Cys Gln Lys Asn 290 295 300 Lys Glu Asn Lys Asn Leu Tyr Lys Leu Arg Lys Leu His Lys Gln Ile 305 310 315 320 Leu Cys Ile Ala Asp Thr Ser Tyr Glu Val Pro Tyr Lys Phe Glu Ser 325 330 335 Asp Glu Glu Val Tyr Gln Ser Val Asn Gly Phe Leu Asp Asn Ile Ser 340 345 350 Ser Lys His Ile Val Glu Arg Leu Arg Lys Ile Gly Asp Asn Tyr Asn 355 360 365 Gly Tyr Asn Leu Asp Lys Ile Tyr Ile Val Ser Lys Phe Tyr Glu Ser 370 375 380 Val Ser Gln Lys Thr Tyr Arg Asp Trp Glu Thr Ile Asn Thr Ala Leu 385 390 395 400 Glu Ile His Tyr Asn Asn Ile Leu Pro Gly Asn Gly Lys Ser Lys Ala 405 410 415 Asp Lys Val Lys Lys Ala Val Lys Asn Asp Leu Gln Lys Ser Ile Thr 420 425 430 Glu Ile Asn Glu Leu Val Ser Asn Tyr Lys Leu Cys Pro Asp Asp Asn 435 440 445 Ile Lys Ala Glu Thr Tyr Ile His Glu Ile Ser His Ile Leu Asn Asn 450 455 460 Phe Glu Ala Gln Glu Leu Lys Tyr Asn Pro Glu Ile His Leu Val Glu 465 470 475 480 Ser Glu Leu Lys Ala Ser Glu Leu Lys Asn Val Leu Asp Val Ile Met 485 490 495 Asn Ala Phe His Trp Cys Ser Val Phe Met Thr Glu Glu Leu Val Asp 500 505 510 Lys Asp Asn Asn Phe Tyr Ala Glu Leu Glu Glu Ile Tyr Asp Glu Ile 515 520 525 Tyr Thr Val Ile Ser Leu Tyr Asn Leu Val Arg Asn Tyr Val Thr Gln 530 535 540 Lys Pro Tyr Ser Thr Lys Lys Ile Lys Leu Asn Phe Gly Ile Pro Thr 545 550 555 560 Leu Ala Asp Gly Trp Ser Lys Ser Lys Glu Tyr Ser Asn Asn Ala Ile 565 570 575 Ile Leu Met Arg Asp Asn Leu Tyr Tyr Leu Gly Ile Phe Asn Ala Lys 580 585 590 Asn Lys Pro Asp Lys Lys Ile Ile Glu Gly Asn Thr Ser Glu Asn Lys 595 600 605 Gly Asp Tyr Lys Lys Met Ile Tyr Asn Leu Leu Pro Gly Pro Asn Lys 610 615 620 Met Ile Pro Lys Val Phe Leu Ser Ser Lys Thr Gly Val Glu Thr Tyr 625 630 635 640 Lys Pro Ser Ala Tyr Ile Leu Glu Gly Tyr Lys Gln Asn Lys His Leu 645 650 655 Lys Ser Ser Lys Asp Phe Asp Ile Thr Phe Cys His Asp Leu Ile Asp 660 665 670 Tyr Phe Lys Asn Cys Ile Ala Ile His Pro Glu Trp Lys Asn Phe Gly 675 680 685 Phe Asp Phe Ser Asp Thr Ser Thr Tyr Glu Asp Ile Ser Gly Phe Tyr 690 695 700 Arg Glu Val Glu Leu Gln Gly Tyr Lys Ile Asp Trp Thr Tyr Ile Ser 705 710 715 720 Glu Lys Asp Ile Asp Leu Leu Gln Glu Lys Gly Gln Leu Tyr Leu Phe 725 730 735 Gln Ile Tyr Asn Lys Asp Phe Ser Lys Lys Ser Thr Gly Asn Asp Asn 740 745 750 Leu His Thr Met Tyr Leu Lys Asn Leu Phe Ser Glu Glu Asn Leu Lys 755 760 765 Asp Ile Val Leu Lys Leu Asn Gly Glu Ala Glu Ile Phe Phe Arg Lys 770 775 780 Ser Ser Ile Lys Asn Pro Ile Ile His Lys Lys Gly Ser Ile Leu Val 785 790 795 800 Asn Arg Thr Tyr Glu Ala Glu Glu Lys Asp Gln Phe Gly Asn Ile Gln 805 810 815 Ile Val Arg Lys Thr Ile Pro Glu Asn Ile Tyr Gln Glu Leu Tyr Lys 820 825 830 Tyr Phe Asn Asp Lys Ser Asp Lys Glu Leu Ser Asp Glu Ala Ala Lys 835 840 845 Leu Lys Asn Val Val Gly His His Glu Ala Ala Thr Asn Ile Val Lys 850 855 860 Asp Tyr Arg Tyr Thr Tyr Asp Lys Tyr Phe Leu His Met Pro Ile Thr 865 870 875 880 Ile Asn Phe Lys Ala Asn Lys Thr Ser Phe Ile Asn Asp Arg Ile Leu 885 890 895 Gln Tyr Ile Ala Lys Glu Lys Asn Leu His Val Ile Gly Ile Asp Arg 900 905 910 Gly Glu Arg Asn Leu Ile Tyr Val Ser Val Ile Asp Thr Cys Gly Asn 915 920 925 Ile Val Glu Gln Lys Ser Phe Asn Ile Val Asn Gly Tyr Asp Tyr Gln 930 935 940 Ile Lys Leu Lys Gln Gln Glu Gly Ala Arg Gln Ile Ala Arg Lys Glu 945 950 955 960 Trp Lys Glu Ile Gly Lys Ile Lys Glu Ile Lys Glu Gly Tyr Leu Ser 965 970 975 Leu Val Ile His Glu Ile Ser Lys Met Val Ile Lys Tyr Asn Ala Ile 980 985 990 Ile Ala Met Glu Asp Leu Ser Tyr Gly Phe Lys Lys Gly Arg Phe Lys 995 1000 1005 Val Glu Arg Gln Val Tyr Gln Lys Phe Glu Thr Met Leu Ile Asn Lys 1010 1015 1020 Leu Asn Tyr Leu Val Phe Lys Asp Ile Ser Ile Thr Glu Asn Gly Gly 1025 1030 1035 1040 Leu Leu Lys Gly Tyr Gln Leu Thr Tyr Ile Pro Asp Lys Leu Lys Asn 1045 1050 1055 Val Gly His Gln Cys Gly Cys Ile Phe Tyr Val Pro Ala Ala Tyr Thr 1060 1065 1070 Ser Lys Ile Asp Pro Thr Thr Gly Phe Val Asn Ile Phe Lys Phe Lys 1075 1080 1085 Asp Leu Thr Val Asp Ala Lys Arg Glu Phe Ile Lys Lys Phe Asp Ser 1090 1095 1100 Ile Arg Tyr Asp Ser Glu Lys Lys Leu Phe Cys Phe Thr Phe Asp Tyr 1105 1110 1115 1120 Asn Asn Phe Ile Thr Gln Asn Thr Val Met Ser Lys Ser Ser Trp Ser 1125 1130 1135 Val Tyr Thr Tyr Gly Val Arg Ile Lys Arg Arg Phe Val Asn Gly Arg 1140 1145 1150 Phe Ser Asn Glu Ser Asp Thr Ile Asp Ile Thr Lys Asp Met Glu Lys 1155 1160 1165 Thr Leu Glu Met Thr Asp Ile Asn Trp Arg Asp Gly His Asp Leu Arg 1170 1175 1180 Gln Asp Ile Ile Asp Tyr Glu Ile Val Gln His Ile Phe Glu Ile Phe 1185 1190 1195 1200 Arg Leu Thr Val Gln Met Arg Asn Ser Leu Ser Glu Leu Glu Asp Arg 1205 1210 1215 Asp Tyr Asp Arg Leu Ile Ser Pro Val Leu Asn Glu Asn Asn Ile Phe 1220 1225 1230 Tyr Asp Ser Ala Lys Ala Gly Asp Ala Leu Pro Lys Asp Ala Asp Ala 1235 1240 1245 Asn Gly Ala Tyr Cys Ile Ala Leu Lys Gly Leu Tyr Glu Ile Lys Gln 1250 1255 1260 Ile Thr Glu Asn Trp Lys Glu Asp Gly Lys Phe Ser Arg Asp Lys Leu 1265 1270 1275 1280 Lys Ile Ser Asn Lys Asp Trp Phe Asp Phe Ile Gln Asn Lys Arg Tyr 1285 1290 1295 Leu Ala Ala Ala Leu Glu Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 1300 1305 1310 Gln Ala Lys Lys Lys Lys Ser Thr Pro Pro Pro Pro Pro Leu Arg Ser 1315 1320 1325 Gly Cys 1330 <210> 2 <211> 3993 <212> DNA <213> Artificial Sequence <220> <223> mgCas12a-1 <400> 2 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atggctagca tgactggtgg acagcaaatg ggtcgcggat ccatgaacaa tggcaccaac 120 aatttccaga actttatcgg aattagcagt ctgcaaaaga ctctccggaa tgcccttata 180 cccaccgaga caacccagca gttcatcgtg aaaaacggga ttatcaagga agacgagctg 240 cgcggcgaaa atcggcaaat tttgaaagat ataatggacg attattaccg cggttttatc 300 tctgagactc tgagctccat tgacgatatc gactggacct cactcttcga aaagatggag 360 attcagctta aaaacggcga taataaggac acactgataa aagaacaggc tgagaagcgg 420 aaagccatct ataagaaatt tgcagatgac gatcgcttca agaacatgtt tagcgccaaa 480 ttgattagtg acatcctgcc ggaattcgtt attcacaata acaattactc tgctagcgag 540 aaggaagaga aaacccaagt cataaagctc ttttcccggt tcgccacttc atttaaagat 600 tatttcaaga accgcgcaaa ttgctttagc gccgacgata tcagttctag ctcctgtcat 660 cggattgtga acgacaatgc tgaaatcttc ttttcaaacg cccttgtata ccgccggatt 720 gtgaaaaatc tgagcaacga tgacataaat aagatcagtg gagatattaa agactctttg 780 aaggagatga gcctggaaga gatctattcc tacgaaaaat atggggagtt cattacccag 840 gaaggcatat cattttacaa cgatatctgc ggtaaggtta atagcttcat gaacctctat 900 tgtcagaaaa ataaggagaa caaaaatctt tacaagctgc gcaaattgca caagcaaatt 960 ctgtgcatcg cagacacaag ttatgaagtc ccttacaaat ttgagtctga tgaagaggtg 1020 tatcagagcg taaacggctt cctcgacaat atttcctcaa agcatatagt ggaacggctt 1080 cgcaaaatcg gagataacta caatgggtat aacctggaca agatttacat cgttagcaaa 1140 ttttatgaga gtgtctctca gaagacctac cgggattggg aaactattaa taccgccttg 1200 gagatacact ataacaatat cctgcccggc aacggtaaaa gcaaggctga caaagtgaag 1260 aaagccgtaa agaatgatct ccaaaaatcc attacagaaa tcaacgagct tgtgtcaaat 1320 tacaagctgt gtccggacga taacattaaa gcagaaacct atatacatga gatcagccac 1380 attttgaata acttcgaagc ccaggagctg aagtacaatc cagaaatcca tctcgttgag 1440 agtgaactta aagcttctga gctgaagaac gtcttggacg tgattatgaa tgcctttcac 1500 tggtgcagcg tattcatgac tgaagagctg gtggataaag acaacaattt ttatgcagaa 1560 ctcgaggaaa tatacgatga gatctatacc gttatttccc tttacaacct ggtccgcaat 1620 tatgtgacac agaagcccta ctcaaccaaa aagatcaaat tgaacttcgg cattccgact 1680 ctggccgacg gatggagcaa gagtaaagaa tattctaata acgctataat cctcatgcgg 1740 gataatcttt actatctggg gatttttaac gccaagaata aacctgacaa gaaaatcatt 1800 gagggcaaca ccagcgaaaa taagggtgat tacaaaaaga tgatatataa cttgctgccc 1860 ggcccgaata aaatgatccc aaaggtattc ctctcctcaa aaacaggagt ggagacctac 1920 aagcccagcg catatattct tgaagggtac aaacaaaaca agcatctgaa aagttctaag 1980 gactttgata tcactttctg tcacgacttg attgattatt ttaaaaattg catagccatc 2040 catccggagt ggaagaactt cggctttgac ttcagcgata cctccacata cgaagacatt 2100 tcaggttttt atcgcgaggt tgaactgcag ggctacaaaa tcgattggac ctatattagc 2160 gagaaggaca tagatctcct tcaggaaaaa ggacaactgt acttgttcca gatctataat 2220 aaggacttta gtaaaaagtc tactgggaac gataatctgc acaccatgta cctcaaaaac 2280 cttttcagcg aggaaaatct gaaggacatt gtcttgaaac tgaacggcga ggctgaaatc 2340 tttttccgga agtcctcaat taaaaatcct ataatccata agaaaggtag cattctcgtg 2400 aaccgcacat atgaggccga agagaaggat cagtttggca atatccaaat tgtacggaaa 2460 accatacccg aaaacatcta ccaggagctt tataagtact tcaatgacaa aagtgataag 2520 gaactgtctg acgaggcagc caaattgaag aacgtggttg gacaccatga agctgccact 2580 aatattgtca aagattatcg ctacacctat gacaagtact ttctgcacat gccgatcaca 2640 attaacttca aagcaaataa gaccagcttt ataaacgatc ggattctcca gtatattgcc 2700 aaagagaaga atcttcatgt gatcgggatt gaccgcggcg aacggaacct gatatacgta 2760 tccgtgatcg atacttgtgg taatattgtt gagcaaaaat cattcaacat cgtcaatggc 2820 tatgactacc agattaagtt gaaacagcaa gaaggagctc gccagatagc ccggaaggag 2880 tggaaggaaa tcgggaaaat taaggagatc aaagaaggct atctgagcct cgtgattcac 2940 gagataagta agatggtaat caaatacaac gcaattatcg ccatggaaga tctttcttat 3000 ggttttaaga aaggccgctt caaggtggag cggcaagttt accagaaatt tgaaaccatg 3060 ctgattaata agttgaacta tctggtcttc aaagacataa gcatcacaga gaatggaggg 3120 ctccttaagg gctaccagct gacctatatt ccagataaat tgaagaacgt gggtcatcaa 3180 tgcggctgta tcttttacgt acccgctgcc tatacttcca aaattgaccc gaccacagga 3240 ttcgtgaata tatttaagtt caaagatctg accgttgacg caaagcgcga atttatcaaa 3300 aagttcgatt caattcggta cgacagcgag aaaaagctct tttgcttcac ttttgattat 3360 aacaatttca tcacccagaa cacagtcatg agtaaatcta gctggtccgt gtacacctat 3420 ggggtacgca ttaagcggcg ctttgtgaat ggccggttct caaacgaaag cgacactata 3480 gatatcacca aagacatgga gaagacactt gaaatgaccg atattaattg gcgcgacggt 3540 cacgatctgc ggcaggacat cattgattac gagatagttc aacatatctt tgaaattttc 3600 cgcttgactg tccagatgcg gaacagtctg tctgagctcg aagaccgcga ttatgaccgg 3660 cttatcagcc ctgtgctgaa tgagaacaat attttttacg attccgccaa agctggcgac 3720 gccttgccca aggatgcaga cgccaacgga gcttattgta tagccctgaa agggctctac 3780 gaaatcaagc agattaccga gaattggaaa gaagatggca agttctcacg cgacaaactt 3840 aagatcagca acaaagattg gtttgacttc attcaaaata agcggtatct ggcggccgca 3900 ctcgagaaaa ggccggcggc cacgaaaaag gccggccagg caaaaaagaa aaagtcgaca 3960 ccaccaccac caccactgag atccggctgc taa 3993 <210> 3 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> myc-NLS <400> 3 ccggcagcca agagagtcaa actcgac 27 <210> 4 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> myc-NLS <400> 4 Pro Ala Ala Lys Arg Val Lys Leu Asp 1 5 <210> 5 <211> 130 <212> DNA <213> Artificial Sequence <220> <223> Core region <400> 5 agccaagaga gtcaaactcg acggcggctc cccagcggca aaaagggtga aactagacgg 60 gggtagcccc gccgcgaagc gtgtaaagct ggatggagga tcgcctgcgg ctaagcgagt 120 caaattagac 130 <210> 6 <211> 99 <212> DNA <213> Artificial Sequence <220> <223> extension primer_forward <400> 6 ttgacttcat tcaaaataag cggtatctgg gcggctcccc tgctgctaaa cgtgttaagc 60 ttgatggggg tagcccggca gccaagagag tcaaactcg 99 <210> 7 <211> 100 <212> DNA <213> Artificial Sequence <220> <223> extension primer_reverse <400> 7 agccggatct cagtggtggt ggtggtggtg gctgccgcta gcatccaatt tgacgcgctt 60 tgcagccggt gacccaccgt ctaatttgac tcgcttagcc 100 <210> 8 <211> 1379 <212> PRT <213> Artificial Sequence <220> <223> mgCas12a-1-6XNLS <400> 8 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg 20 25 30 Gly Ser Met Asn Asn Gly Thr Asn Asn Phe Gln Asn Phe Ile Gly Ile 35 40 45 Ser Ser Leu Gln Lys Thr Leu Arg Asn Ala Leu Ile Pro Thr Glu Thr 50 55 60 Thr Gln Gln Phe Ile Val Lys Asn Gly Ile Ile Lys Glu Asp Glu Leu 65 70 75 80 Arg Gly Glu Asn Arg Gln Ile Leu Lys Asp Ile Met Asp Asp Tyr Tyr 85 90 95 Arg Gly Phe Ile Ser Glu Thr Leu Ser Ser Ile Asp Asp Ile Asp Trp 100 105 110 Thr Ser Leu Phe Glu Lys Met Glu Ile Gln Leu Lys Asn Gly Asp Asn 115 120 125 Lys Asp Thr Leu Ile Lys Glu Gln Ala Glu Lys Arg Lys Ala Ile Tyr 130 135 140 Lys Lys Phe Ala Asp Asp Asp Arg Phe Lys Asn Met Phe Ser Ala Lys 145 150 155 160 Leu Ile Ser Asp Ile Leu Pro Glu Phe Val Ile His Asn Asn Asn Tyr 165 170 175 Ser Ala Ser Glu Lys Glu Glu Lys Thr Gln Val Ile Lys Leu Phe Ser 180 185 190 Arg Phe Ala Thr Ser Phe Lys Asp Tyr Phe Lys Asn Arg Ala Asn Cys 195 200 205 Phe Ser Ala Asp Asp Ile Ser Ser Ser Ser Cys His Arg Ile Val Asn 210 215 220 Asp Asn Ala Glu Ile Phe Phe Ser Asn Ala Leu Val Tyr Arg Arg Ile 225 230 235 240 Val Lys Asn Leu Ser Asn Asp Asp Ile Asn Lys Ile Ser Gly Asp Ile 245 250 255 Lys Asp Ser Leu Lys Glu Met Ser Leu Glu Glu Ile Tyr Ser Tyr Glu 260 265 270 Lys Tyr Gly Glu Phe Ile Thr Gln Glu Gly Ile Ser Phe Tyr Asn Asp 275 280 285 Ile Cys Gly Lys Val Asn Ser Phe Met Asn Leu Tyr Cys Gln Lys Asn 290 295 300 Lys Glu Asn Lys Asn Leu Tyr Lys Leu Arg Lys Leu His Lys Gln Ile 305 310 315 320 Leu Cys Ile Ala Asp Thr Ser Tyr Glu Val Pro Tyr Lys Phe Glu Ser 325 330 335 Asp Glu Glu Val Tyr Gln Ser Val Asn Gly Phe Leu Asp Asn Ile Ser 340 345 350 Ser Lys His Ile Val Glu Arg Leu Arg Lys Ile Gly Asp Asn Tyr Asn 355 360 365 Gly Tyr Asn Leu Asp Lys Ile Tyr Ile Val Ser Lys Phe Tyr Glu Ser 370 375 380 Val Ser Gln Lys Thr Tyr Arg Asp Trp Glu Thr Ile Asn Thr Ala Leu 385 390 395 400 Glu Ile His Tyr Asn Asn Ile Leu Pro Gly Asn Gly Lys Ser Lys Ala 405 410 415 Asp Lys Val Lys Lys Ala Val Lys Asn Asp Leu Gln Lys Ser Ile Thr 420 425 430 Glu Ile Asn Glu Leu Val Ser Asn Tyr Lys Leu Cys Pro Asp Asp Asn 435 440 445 Ile Lys Ala Glu Thr Tyr Ile His Glu Ile Ser His Ile Leu Asn Asn 450 455 460 Phe Glu Ala Gln Glu Leu Lys Tyr Asn Pro Glu Ile His Leu Val Glu 465 470 475 480 Ser Glu Leu Lys Ala Ser Glu Leu Lys Asn Val Leu Asp Val Ile Met 485 490 495 Asn Ala Phe His Trp Cys Ser Val Phe Met Thr Glu Glu Leu Val Asp 500 505 510 Lys Asp Asn Asn Phe Tyr Ala Glu Leu Glu Glu Ile Tyr Asp Glu Ile 515 520 525 Tyr Thr Val Ile Ser Leu Tyr Asn Leu Val Arg Asn Tyr Val Thr Gln 530 535 540 Lys Pro Tyr Ser Thr Lys Lys Ile Lys Leu Asn Phe Gly Ile Pro Thr 545 550 555 560 Leu Ala Asp Gly Trp Ser Lys Ser Lys Glu Tyr Ser Asn Asn Ala Ile 565 570 575 Ile Leu Met Arg Asp Asn Leu Tyr Tyr Leu Gly Ile Phe Asn Ala Lys 580 585 590 Asn Lys Pro Asp Lys Lys Ile Ile Glu Gly Asn Thr Ser Glu Asn Lys 595 600 605 Gly Asp Tyr Lys Lys Met Ile Tyr Asn Leu Leu Pro Gly Pro Asn Lys 610 615 620 Met Ile Pro Lys Val Phe Leu Ser Ser Lys Thr Gly Val Glu Thr Tyr 625 630 635 640 Lys Pro Ser Ala Tyr Ile Leu Glu Gly Tyr Lys Gln Asn Lys His Leu 645 650 655 Lys Ser Ser Lys Asp Phe Asp Ile Thr Phe Cys His Asp Leu Ile Asp 660 665 670 Tyr Phe Lys Asn Cys Ile Ala Ile His Pro Glu Trp Lys Asn Phe Gly 675 680 685 Phe Asp Phe Ser Asp Thr Ser Thr Tyr Glu Asp Ile Ser Gly Phe Tyr 690 695 700 Arg Glu Val Glu Leu Gln Gly Tyr Lys Ile Asp Trp Thr Tyr Ile Ser 705 710 715 720 Glu Lys Asp Ile Asp Leu Leu Gln Glu Lys Gly Gln Leu Tyr Leu Phe 725 730 735 Gln Ile Tyr Asn Lys Asp Phe Ser Lys Lys Ser Thr Gly Asn Asp Asn 740 745 750 Leu His Thr Met Tyr Leu Lys Asn Leu Phe Ser Glu Glu Asn Leu Lys 755 760 765 Asp Ile Val Leu Lys Leu Asn Gly Glu Ala Glu Ile Phe Phe Arg Lys 770 775 780 Ser Ser Ile Lys Asn Pro Ile Ile His Lys Lys Gly Ser Ile Leu Val 785 790 795 800 Asn Arg Thr Tyr Glu Ala Glu Glu Lys Asp Gln Phe Gly Asn Ile Gln 805 810 815 Ile Val Arg Lys Thr Ile Pro Glu Asn Ile Tyr Gln Glu Leu Tyr Lys 820 825 830 Tyr Phe Asn Asp Lys Ser Asp Lys Glu Leu Ser Asp Glu Ala Ala Lys 835 840 845 Leu Lys Asn Val Val Gly His His Glu Ala Ala Thr Asn Ile Val Lys 850 855 860 Asp Tyr Arg Tyr Thr Tyr Asp Lys Tyr Phe Leu His Met Pro Ile Thr 865 870 875 880 Ile Asn Phe Lys Ala Asn Lys Thr Ser Phe Ile Asn Asp Arg Ile Leu 885 890 895 Gln Tyr Ile Ala Lys Glu Lys Asn Leu His Val Ile Gly Ile Asp Arg 900 905 910 Gly Glu Arg Asn Leu Ile Tyr Val Ser Val Ile Asp Thr Cys Gly Asn 915 920 925 Ile Val Glu Gln Lys Ser Phe Asn Ile Val Asn Gly Tyr Asp Tyr Gln 930 935 940 Ile Lys Leu Lys Gln Gln Glu Gly Ala Arg Gln Ile Ala Arg Lys Glu 945 950 955 960 Trp Lys Glu Ile Gly Lys Ile Lys Glu Ile Lys Glu Gly Tyr Leu Ser 965 970 975 Leu Val Ile His Glu Ile Ser Lys Met Val Ile Lys Tyr Asn Ala Ile 980 985 990 Ile Ala Met Glu Asp Leu Ser Tyr Gly Phe Lys Lys Gly Arg Phe Lys 995 1000 1005 Val Glu Arg Gln Val Tyr Gln Lys Phe Glu Thr Met Leu Ile Asn Lys 1010 1015 1020 Leu Asn Tyr Leu Val Phe Lys Asp Ile Ser Ile Thr Glu Asn Gly Gly 1025 1030 1035 1040 Leu Leu Lys Gly Tyr Gln Leu Thr Tyr Ile Pro Asp Lys Leu Lys Asn 1045 1050 1055 Val Gly His Gln Cys Gly Cys Ile Phe Tyr Val Pro Ala Ala Tyr Thr 1060 1065 1070 Ser Lys Ile Asp Pro Thr Thr Gly Phe Val Asn Ile Phe Lys Phe Lys 1075 1080 1085 Asp Leu Thr Val Asp Ala Lys Arg Glu Phe Ile Lys Lys Phe Asp Ser 1090 1095 1100 Ile Arg Tyr Asp Ser Glu Lys Lys Leu Phe Cys Phe Thr Phe Asp Tyr 1105 1110 1115 1120 Asn Asn Phe Ile Thr Gln Asn Thr Val Met Ser Lys Ser Ser Trp Ser 1125 1130 1135 Val Tyr Thr Tyr Gly Val Arg Ile Lys Arg Arg Phe Val Asn Gly Arg 1140 1145 1150 Phe Ser Asn Glu Ser Asp Thr Ile Asp Ile Thr Lys Asp Met Glu Lys 1155 1160 1165 Thr Leu Glu Met Thr Asp Ile Asn Trp Arg Asp Gly His Asp Leu Arg 1170 1175 1180 Gln Asp Ile Ile Asp Tyr Glu Ile Val Gln His Ile Phe Glu Ile Phe 1185 1190 1195 1200 Arg Leu Thr Val Gln Met Arg Asn Ser Leu Ser Glu Leu Glu Asp Arg 1205 1210 1215 Asp Tyr Asp Arg Leu Ile Ser Pro Val Leu Asn Glu Asn Asn Ile Phe 1220 1225 1230 Tyr Asp Ser Ala Lys Ala Gly Asp Ala Leu Pro Lys Asp Ala Asp Ala 1235 1240 1245 Asn Gly Ala Tyr Cys Ile Ala Leu Lys Gly Leu Tyr Glu Ile Lys Gln 1250 1255 1260 Ile Thr Glu Asn Trp Lys Glu Asp Gly Lys Phe Ser Arg Asp Lys Leu 1265 1270 1275 1280 Lys Ile Ser Asn Lys Asp Trp Phe Asp Phe Ile Gln Asn Lys Arg Tyr 1285 1290 1295 Leu Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser 1300 1305 1310 Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser Pro Ala Ala Lys 1315 1320 1325 Arg Val Lys Leu Asp Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu 1330 1335 1340 Asp Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser 1345 1350 1355 1360 Pro Ala Ala Lys Arg Val Lys Leu Asp Ala Ser Gly Ser His His His 1365 1370 1375 His His His <210> 9 <211> 4140 <212> DNA <213> Artificial Sequence <220> <223> mgCas12a-1-6XNLS <400> 9 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atggctagca tgactggtgg acagcaaatg ggtcgcggat ccatgaacaa tggcaccaac 120 aatttccaga actttatcgg aattagcagt ctgcaaaaga ctctccggaa tgcccttata 180 cccaccgaga caacccagca gttcatcgtg aaaaacggga ttatcaagga agacgagctg 240 cgcggcgaaa atcggcaaat tttgaaagat ataatggacg attattaccg cggttttatc 300 tctgagactc tgagctccat tgacgatatc gactggacct cactcttcga aaagatggag 360 attcagctta aaaacggcga taataaggac acactgataa aagaacaggc tgagaagcgg 420 aaagccatct ataagaaatt tgcagatgac gatcgcttca agaacatgtt tagcgccaaa 480 ttgattagtg acatcctgcc ggaattcgtt attcacaata acaattactc tgctagcgag 540 aaggaagaga aaacccaagt cataaagctc ttttcccggt tcgccacttc atttaaagat 600 tatttcaaga accgcgcaaa ttgctttagc gccgacgata tcagttctag ctcctgtcat 660 cggattgtga acgacaatgc tgaaatcttc ttttcaaacg cccttgtata ccgccggatt 720 gtgaaaaatc tgagcaacga tgacataaat aagatcagtg gagatattaa agactctttg 780 aaggagatga gcctggaaga gatctattcc tacgaaaaat atggggagtt cattacccag 840 gaaggcatat cattttacaa cgatatctgc ggtaaggtta atagcttcat gaacctctat 900 tgtcagaaaa ataaggagaa caaaaatctt tacaagctgc gcaaattgca caagcaaatt 960 ctgtgcatcg cagacacaag ttatgaagtc ccttacaaat ttgagtctga tgaagaggtg 1020 tatcagagcg taaacggctt cctcgacaat atttcctcaa agcatatagt ggaacggctt 1080 cgcaaaatcg gagataacta caatgggtat aacctggaca agatttacat cgttagcaaa 1140 ttttatgaga gtgtctctca gaagacctac cgggattggg aaactattaa taccgccttg 1200 gagatacact ataacaatat cctgcccggc aacggtaaaa gcaaggctga caaagtgaag 1260 aaagccgtaa agaatgatct ccaaaaatcc attacagaaa tcaacgagct tgtgtcaaat 1320 tacaagctgt gtccggacga taacattaaa gcagaaacct atatacatga gatcagccac 1380 attttgaata acttcgaagc ccaggagctg aagtacaatc cagaaatcca tctcgttgag 1440 agtgaactta aagcttctga gctgaagaac gtcttggacg tgattatgaa tgcctttcac 1500 tggtgcagcg tattcatgac tgaagagctg gtggataaag acaacaattt ttatgcagaa 1560 ctcgaggaaa tatacgatga gatctatacc gttatttccc tttacaacct ggtccgcaat 1620 tatgtgacac agaagcccta ctcaaccaaa aagatcaaat tgaacttcgg cattccgact 1680 ctggccgacg gatggagcaa gagtaaagaa tattctaata acgctataat cctcatgcgg 1740 gataatcttt actatctggg gatttttaac gccaagaata aacctgacaa gaaaatcatt 1800 gagggcaaca ccagcgaaaa taagggtgat tacaaaaaga tgatatataa cttgctgccc 1860 ggcccgaata aaatgatccc aaaggtattc ctctcctcaa aaacaggagt ggagacctac 1920 aagcccagcg catatattct tgaagggtac aaacaaaaca agcatctgaa aagttctaag 1980 gactttgata tcactttctg tcacgacttg attgattatt ttaaaaattg catagccatc 2040 catccggagt ggaagaactt cggctttgac ttcagcgata cctccacata cgaagacatt 2100 tcaggttttt atcgcgaggt tgaactgcag ggctacaaaa tcgattggac ctatattagc 2160 gagaaggaca tagatctcct tcaggaaaaa ggacaactgt acttgttcca gatctataat 2220 aaggacttta gtaaaaagtc tactgggaac gataatctgc acaccatgta cctcaaaaac 2280 cttttcagcg aggaaaatct gaaggacatt gtcttgaaac tgaacggcga ggctgaaatc 2340 tttttccgga agtcctcaat taaaaatcct ataatccata agaaaggtag cattctcgtg 2400 aaccgcacat atgaggccga agagaaggat cagtttggca atatccaaat tgtacggaaa 2460 accatacccg aaaacatcta ccaggagctt tataagtact tcaatgacaa aagtgataag 2520 gaactgtctg acgaggcagc caaattgaag aacgtggttg gacaccatga agctgccact 2580 aatattgtca aagattatcg ctacacctat gacaagtact ttctgcacat gccgatcaca 2640 attaacttca aagcaaataa gaccagcttt ataaacgatc ggattctcca gtatattgcc 2700 aaagagaaga atcttcatgt gatcgggatt gaccgcggcg aacggaacct gatatacgta 2760 tccgtgatcg atacttgtgg taatattgtt gagcaaaaat cattcaacat cgtcaatggc 2820 tatgactacc agattaagtt gaaacagcaa gaaggagctc gccagatagc ccggaaggag 2880 tggaaggaaa tcgggaaaat taaggagatc aaagaaggct atctgagcct cgtgattcac 2940 gagataagta agatggtaat caaatacaac gcaattatcg ccatggaaga tctttcttat 3000 ggttttaaga aaggccgctt caaggtggag cggcaagttt accagaaatt tgaaaccatg 3060 ctgattaata agttgaacta tctggtcttc aaagacataa gcatcacaga gaatggaggg 3120 ctccttaagg gctaccagct gacctatatt ccagataaat tgaagaacgt gggtcatcaa 3180 tgcggctgta tcttttacgt acccgctgcc tatacttcca aaattgaccc gaccacagga 3240 ttcgtgaata tatttaagtt caaagatctg accgttgacg caaagcgcga atttatcaaa 3300 aagttcgatt caattcggta cgacagcgag aaaaagctct tttgcttcac ttttgattat 3360 aacaatttca tcacccagaa cacagtcatg agtaaatcta gctggtccgt gtacacctat 3420 ggggtacgca ttaagcggcg ctttgtgaat ggccggttct caaacgaaag cgacactata 3480 gatatcacca aagacatgga gaagacactt gaaatgaccg atattaattg gcgcgacggt 3540 cacgatctgc ggcaggacat cattgattac gagatagttc aacatatctt tgaaattttc 3600 cgcttgactg tccagatgcg gaacagtctg tctgagctcg aagaccgcga ttatgaccgg 3660 cttatcagcc ctgtgctgaa tgagaacaat attttttacg attccgccaa agctggcgac 3720 gccttgccca aggatgcaga cgccaacgga gcttattgta tagccctgaa agggctctac 3780 gaaatcaagc agattaccga gaattggaaa gaagatggca agttctcacg cgacaaactt 3840 aagatcagca acaaagattg gtttgacttc attcaaaata agcggtatct gggcggctcc 3900 cctgctgcta aacgtgttaa gcttgatggg ggtagcccgg cagccaagag agtcaaactc 3960 gacggcggct ccccagcggc aaaaagggtg aaactagacg ggggtagccc cgccgcgaag 4020 cgtgtaaagc tggatggagg atcgcctgcg gctaagcgag tcaaattaga cggtgggtca 4080 ccggctgcaa agcgcgtcaa attggatgct agcggcagcc accaccacca ccaccactga 4140 4140 <210> 10 <211> 164 <212> DNA <213> Artificial Sequence <220> <223> insert1 <400> 10 gcgccaaatt gattagtgac atcctgccgg aattcgttat tcacaataac aattactctg 60 ctagcgagaa ggaagagaaa acccaagtca taaagctctt ttcccggttc gccacttcat 120 ttaaagatta tttccgcaac cgcgcaaatt gctttagcgc cgac 164 <210> 11 <211> 53 <212> DNA <213> Artificial Sequence <220> <223> insert1_primer_forward <400> 11 gcgccaaatt gattagtgac atcctgccgg aattcgttat tcacaataac aat 53 <210> 12 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> insert1_primer_reverse <400> 12 gtcggcgcta aagcaatttg cgcggttgcg gaaataatct ttaaatgaag tggc 54 <210> 13 <211> 1083 <212> DNA <213> Artificial Sequence <220> <223> insert2 <400> 13 cgcaaccgcg caaattgctt tagcgccgac gatatcagtt ctagctcctg tcatcggatt 60 gtgaacgaca atgctgaaat cttcttttca aacgcccttg tataccgccg gattgtgaaa 120 aatctgagca acgatgacat aaataagatc agtggagata ttaaagactc tttgaaggag 180 atgagcctgg aagagatcta ttcctacgaa aaatatgggg agttcattac ccaggaaggc 240 atatcatttt acaacgatat ctgcggtaag gttaatagct tcatgaacct ctattgtcag 300 aaaaataagg agaacaaaaa tctttacaag ctgcgcaaat tgcacaagca aattctgtgc 360 atcgcagaca caagttatga agtcccttac aaatttgagt ctgatgaaga ggtgtatcag 420 agcgtaaacg gcttcctcga caatatttcc tcaaagcata tagtggaacg gcttcgcaaa 480 atcggagata actacaatgg gtataacctg gacaagattt acatcgttag caaattttat 540 gagagtgtct ctcagaagac ctaccgggat tgggaaacta ttaataccgc cttggagata 600 cactataaca atatcctgcc cggcaacggt aaaagcaagg ctgacaaagt gaagaaagcc 660 gtaaagaatg atctccaaaa atccattaca gaaatcaacg agcttgtgtc aaattacaag 720 ctgtgtccgg acgataacat taaagcagaa acctatatac atgagatcag ccacattttg 780 aataacttcg aagcccagga gctgaagtac aatccagaaa tccatctcgt tgagagtgaa 840 cttaaagctt ctgagctgaa gaacgtcttg gacgtgatta tgaatgcctt tcactggtgc 900 agcgtattca tgactgaaga gctggtggat aaagacaaca atttttatgc agaactcgag 960 gaaatatacg atgagatcta taccgttatt tccctttaca acctggtccg caattatgtg 1020 acacagaagc cctactcaac caaaaagatc aaattgaact tcggcattcc gactctggcc 1080 cgc 1083 <210> 14 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> insert2_primer_forward <400> 14 cgcaaccgcg caaattgctt tagcgccgac 30 <210> 15 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> insert2_primer_reverse <400> 15 gcgggccaga gtcggaatgc cgaagttcaa 30 <210> 16 <211> 281 <212> DNA <213> Artificial Sequence <220> <223> insert3 <400> 16 ttgaacttcg gcattccgac tctggcccgc ggatggagca agagtaaaga atattctaat 60 aacgctataa tcctcatgcg ggataatctt tactatctgg ggatttttaa cgccaagaat 120 aaacctgaca agaaaatcat tgagggcaac accagcgaaa ataagggtga ttacaaaaag 180 atgatatata acttgctgcc cggcccgaat aaaatgatcc caaaggtatt cctctcctca 240 aaaacaggag tggagaccta caagcccagc gcatatattc t 281 <210> 17 <211> 50 <212> DNA <213> Artificial Sequence <220> <223> insert3_primer_forward <400> 17 ttgaacttcg gcattccgac tctggcccgc ggatggagca agagtaaaga 50 <210> 18 <211> 50 <212> DNA <213> Artificial Sequence <220> <223> insert3_primer_reverse <400> 18 agaatatatg cgctgggctt gtaggtctcc actcctgttt ttgaggagag 50 <210> 19 <211> 1379 <212> PRT <213> Artificial Sequence <220> <223> opmgCas12a-1-6XNLS <400> 19 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg 20 25 30 Gly Ser Met Asn Asn Gly Thr Asn Asn Phe Gln Asn Phe Ile Gly Ile 35 40 45 Ser Ser Leu Gln Lys Thr Leu Arg Asn Ala Leu Ile Pro Thr Glu Thr 50 55 60 Thr Gln Gln Phe Ile Val Lys Asn Gly Ile Ile Lys Glu Asp Glu Leu 65 70 75 80 Arg Gly Glu Asn Arg Gln Ile Leu Lys Asp Ile Met Asp Asp Tyr Tyr 85 90 95 Arg Gly Phe Ile Ser Glu Thr Leu Ser Ser Ile Asp Asp Ile Asp Trp 100 105 110 Thr Ser Leu Phe Glu Lys Met Glu Ile Gln Leu Lys Asn Gly Asp Asn 115 120 125 Lys Asp Thr Leu Ile Lys Glu Gln Ala Glu Lys Arg Lys Ala Ile Tyr 130 135 140 Lys Lys Phe Ala Asp Asp Asp Arg Phe Lys Asn Met Phe Ser Ala Lys 145 150 155 160 Leu Ile Ser Asp Ile Leu Pro Glu Phe Val Ile His Asn Asn Asn Tyr 165 170 175 Ser Ala Ser Glu Lys Glu Glu Lys Thr Gln Val Ile Lys Leu Phe Ser 180 185 190 Arg Phe Ala Thr Ser Phe Lys Asp Tyr Phe Arg Asn Arg Ala Asn Cys 195 200 205 Phe Ser Ala Asp Asp Ile Ser Ser Ser Ser Cys His Arg Ile Val Asn 210 215 220 Asp Asn Ala Glu Ile Phe Phe Ser Asn Ala Leu Val Tyr Arg Arg Ile 225 230 235 240 Val Lys Asn Leu Ser Asn Asp Asp Ile Asn Lys Ile Ser Gly Asp Ile 245 250 255 Lys Asp Ser Leu Lys Glu Met Ser Leu Glu Glu Ile Tyr Ser Tyr Glu 260 265 270 Lys Tyr Gly Glu Phe Ile Thr Gln Glu Gly Ile Ser Phe Tyr Asn Asp 275 280 285 Ile Cys Gly Lys Val Asn Ser Phe Met Asn Leu Tyr Cys Gln Lys Asn 290 295 300 Lys Glu Asn Lys Asn Leu Tyr Lys Leu Arg Lys Leu His Lys Gln Ile 305 310 315 320 Leu Cys Ile Ala Asp Thr Ser Tyr Glu Val Pro Tyr Lys Phe Glu Ser 325 330 335 Asp Glu Glu Val Tyr Gln Ser Val Asn Gly Phe Leu Asp Asn Ile Ser 340 345 350 Ser Lys His Ile Val Glu Arg Leu Arg Lys Ile Gly Asp Asn Tyr Asn 355 360 365 Gly Tyr Asn Leu Asp Lys Ile Tyr Ile Val Ser Lys Phe Tyr Glu Ser 370 375 380 Val Ser Gln Lys Thr Tyr Arg Asp Trp Glu Thr Ile Asn Thr Ala Leu 385 390 395 400 Glu Ile His Tyr Asn Asn Ile Leu Pro Gly Asn Gly Lys Ser Lys Ala 405 410 415 Asp Lys Val Lys Lys Ala Val Lys Asn Asp Leu Gln Lys Ser Ile Thr 420 425 430 Glu Ile Asn Glu Leu Val Ser Asn Tyr Lys Leu Cys Pro Asp Asp Asn 435 440 445 Ile Lys Ala Glu Thr Tyr Ile His Glu Ile Ser His Ile Leu Asn Asn 450 455 460 Phe Glu Ala Gln Glu Leu Lys Tyr Asn Pro Glu Ile His Leu Val Glu 465 470 475 480 Ser Glu Leu Lys Ala Ser Glu Leu Lys Asn Val Leu Asp Val Ile Met 485 490 495 Asn Ala Phe His Trp Cys Ser Val Phe Met Thr Glu Glu Leu Val Asp 500 505 510 Lys Asp Asn Asn Phe Tyr Ala Glu Leu Glu Glu Ile Tyr Asp Glu Ile 515 520 525 Tyr Thr Val Ile Ser Leu Tyr Asn Leu Val Arg Asn Tyr Val Thr Gln 530 535 540 Lys Pro Tyr Ser Thr Lys Lys Ile Lys Leu Asn Phe Gly Ile Pro Thr 545 550 555 560 Leu Ala Arg Gly Trp Ser Lys Ser Lys Glu Tyr Ser Asn Asn Ala Ile 565 570 575 Ile Leu Met Arg Asp Asn Leu Tyr Tyr Leu Gly Ile Phe Asn Ala Lys 580 585 590 Asn Lys Pro Asp Lys Lys Ile Ile Glu Gly Asn Thr Ser Glu Asn Lys 595 600 605 Gly Asp Tyr Lys Lys Met Ile Tyr Asn Leu Leu Pro Gly Pro Asn Lys 610 615 620 Met Ile Pro Lys Val Phe Leu Ser Ser Lys Thr Gly Val Glu Thr Tyr 625 630 635 640 Lys Pro Ser Ala Tyr Ile Leu Glu Gly Tyr Lys Gln Asn Lys His Leu 645 650 655 Lys Ser Ser Lys Asp Phe Asp Ile Thr Phe Cys His Asp Leu Ile Asp 660 665 670 Tyr Phe Lys Asn Cys Ile Ala Ile His Pro Glu Trp Lys Asn Phe Gly 675 680 685 Phe Asp Phe Ser Asp Thr Ser Thr Tyr Glu Asp Ile Ser Gly Phe Tyr 690 695 700 Arg Glu Val Glu Leu Gln Gly Tyr Lys Ile Asp Trp Thr Tyr Ile Ser 705 710 715 720 Glu Lys Asp Ile Asp Leu Leu Gln Glu Lys Gly Gln Leu Tyr Leu Phe 725 730 735 Gln Ile Tyr Asn Lys Asp Phe Ser Lys Lys Ser Thr Gly Asn Asp Asn 740 745 750 Leu His Thr Met Tyr Leu Lys Asn Leu Phe Ser Glu Glu Asn Leu Lys 755 760 765 Asp Ile Val Leu Lys Leu Asn Gly Glu Ala Glu Ile Phe Phe Arg Lys 770 775 780 Ser Ser Ile Lys Asn Pro Ile Ile His Lys Lys Gly Ser Ile Leu Val 785 790 795 800 Asn Arg Thr Tyr Glu Ala Glu Glu Lys Asp Gln Phe Gly Asn Ile Gln 805 810 815 Ile Val Arg Lys Thr Ile Pro Glu Asn Ile Tyr Gln Glu Leu Tyr Lys 820 825 830 Tyr Phe Asn Asp Lys Ser Asp Lys Glu Leu Ser Asp Glu Ala Ala Lys 835 840 845 Leu Lys Asn Val Val Gly His His Glu Ala Ala Thr Asn Ile Val Lys 850 855 860 Asp Tyr Arg Tyr Thr Tyr Asp Lys Tyr Phe Leu His Met Pro Ile Thr 865 870 875 880 Ile Asn Phe Lys Ala Asn Lys Thr Ser Phe Ile Asn Asp Arg Ile Leu 885 890 895 Gln Tyr Ile Ala Lys Glu Lys Asn Leu His Val Ile Gly Ile Asp Arg 900 905 910 Gly Glu Arg Asn Leu Ile Tyr Val Ser Val Ile Asp Thr Cys Gly Asn 915 920 925 Ile Val Glu Gln Lys Ser Phe Asn Ile Val Asn Gly Tyr Asp Tyr Gln 930 935 940 Ile Lys Leu Lys Gln Gln Glu Gly Ala Arg Gln Ile Ala Arg Lys Glu 945 950 955 960 Trp Lys Glu Ile Gly Lys Ile Lys Glu Ile Lys Glu Gly Tyr Leu Ser 965 970 975 Leu Val Ile His Glu Ile Ser Lys Met Val Ile Lys Tyr Asn Ala Ile 980 985 990 Ile Ala Met Glu Asp Leu Ser Tyr Gly Phe Lys Lys Gly Arg Phe Lys 995 1000 1005 Val Glu Arg Gln Val Tyr Gln Lys Phe Glu Thr Met Leu Ile Asn Lys 1010 1015 1020 Leu Asn Tyr Leu Val Phe Lys Asp Ile Ser Ile Thr Glu Asn Gly Gly 1025 1030 1035 1040 Leu Leu Lys Gly Tyr Gln Leu Thr Tyr Ile Pro Asp Lys Leu Lys Asn 1045 1050 1055 Val Gly His Gln Cys Gly Cys Ile Phe Tyr Val Pro Ala Ala Tyr Thr 1060 1065 1070 Ser Lys Ile Asp Pro Thr Thr Gly Phe Val Asn Ile Phe Lys Phe Lys 1075 1080 1085 Asp Leu Thr Val Asp Ala Lys Arg Glu Phe Ile Lys Lys Phe Asp Ser 1090 1095 1100 Ile Arg Tyr Asp Ser Glu Lys Lys Leu Phe Cys Phe Thr Phe Asp Tyr 1105 1110 1115 1120 Asn Asn Phe Ile Thr Gln Asn Thr Val Met Ser Lys Ser Ser Trp Ser 1125 1130 1135 Val Tyr Thr Tyr Gly Val Arg Ile Lys Arg Arg Phe Val Asn Gly Arg 1140 1145 1150 Phe Ser Asn Glu Ser Asp Thr Ile Asp Ile Thr Lys Asp Met Glu Lys 1155 1160 1165 Thr Leu Glu Met Thr Asp Ile Asn Trp Arg Asp Gly His Asp Leu Arg 1170 1175 1180 Gln Asp Ile Ile Asp Tyr Glu Ile Val Gln His Ile Phe Glu Ile Phe 1185 1190 1195 1200 Arg Leu Thr Val Gln Met Arg Asn Ser Leu Ser Glu Leu Glu Asp Arg 1205 1210 1215 Asp Tyr Asp Arg Leu Ile Ser Pro Val Leu Asn Glu Asn Asn Ile Phe 1220 1225 1230 Tyr Asp Ser Ala Lys Ala Gly Asp Ala Leu Pro Lys Asp Ala Asp Ala 1235 1240 1245 Asn Gly Ala Tyr Cys Ile Ala Leu Lys Gly Leu Tyr Glu Ile Lys Gln 1250 1255 1260 Ile Thr Glu Asn Trp Lys Glu Asp Gly Lys Phe Ser Arg Asp Lys Leu 1265 1270 1275 1280 Lys Ile Ser Asn Lys Asp Trp Phe Asp Phe Ile Gln Asn Lys Arg Tyr 1285 1290 1295 Leu Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser 1300 1305 1310 Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser Pro Ala Ala Lys 1315 1320 1325 Arg Val Lys Leu Asp Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu 1330 1335 1340 Asp Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser 1345 1350 1355 1360 Pro Ala Ala Lys Arg Val Lys Leu Asp Ala Ser Gly Ser His His His 1365 1370 1375 His His His <210> 20 <211> 4140 <212> DNA <213> Artificial Sequence <220> <223> opmgCas12a-1-6XNLS <400> 20 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atggctagca tgactggtgg acagcaaatg ggtcgcggat ccatgaacaa tggcaccaac 120 aatttccaga actttatcgg aattagcagt ctgcaaaaga ctctccggaa tgcccttata 180 cccaccgaga caacccagca gttcatcgtg aaaaacggga ttatcaagga agacgagctg 240 cgcggcgaaa atcggcaaat tttgaaagat ataatggacg attattaccg cggttttatc 300 tctgagactc tgagctccat tgacgatatc gactggacct cactcttcga aaagatggag 360 attcagctta aaaacggcga taataaggac acactgataa aagaacaggc tgagaagcgg 420 aaagccatct ataagaaatt tgcagatgac gatcgcttca agaacatgtt tagcgccaaa 480 ttgattagtg acatcctgcc ggaattcgtt attcacaata acaattactc tgctagcgag 540 aaggaagaga aaacccaagt cataaagctc ttttcccggt tcgccacttc atttaaagat 600 tatttccgca accgcgcaaa ttgctttagc gccgacgata tcagttctag ctcctgtcat 660 cggattgtga acgacaatgc tgaaatcttc ttttcaaacg cccttgtata ccgccggatt 720 gtgaaaaatc tgagcaacga tgacataaat aagatcagtg gagatattaa agactctttg 780 aaggagatga gcctggaaga gatctattcc tacgaaaaat atggggagtt cattacccag 840 gaaggcatat cattttacaa cgatatctgc ggtaaggtta atagcttcat gaacctctat 900 tgtcagaaaa ataaggagaa caaaaatctt tacaagctgc gcaaattgca caagcaaatt 960 ctgtgcatcg cagacacaag ttatgaagtc ccttacaaat ttgagtctga tgaagaggtg 1020 tatcagagcg taaacggctt cctcgacaat atttcctcaa agcatatagt ggaacggctt 1080 cgcaaaatcg gagataacta caatgggtat aacctggaca agatttacat cgttagcaaa 1140 ttttatgaga gtgtctctca gaagacctac cgggattggg aaactattaa taccgccttg 1200 gagatacact ataacaatat cctgcccggc aacggtaaaa gcaaggctga caaagtgaag 1260 aaagccgtaa agaatgatct ccaaaaatcc attacagaaa tcaacgagct tgtgtcaaat 1320 tacaagctgt gtccggacga taacattaaa gcagaaacct atatacatga gatcagccac 1380 attttgaata acttcgaagc ccaggagctg aagtacaatc cagaaatcca tctcgttgag 1440 agtgaactta aagcttctga gctgaagaac gtcttggacg tgattatgaa tgcctttcac 1500 tggtgcagcg tattcatgac tgaagagctg gtggataaag acaacaattt ttatgcagaa 1560 ctcgaggaaa tatacgatga gatctatacc gttatttccc tttacaacct ggtccgcaat 1620 tatgtgacac agaagcccta ctcaaccaaa aagatcaaat tgaacttcgg cattccgact 1680 ctggcccgcg gatggagcaa gagtaaagaa tattctaata acgctataat cctcatgcgg 1740 gataatcttt actatctggg gatttttaac gccaagaata aacctgacaa gaaaatcatt 1800 gagggcaaca ccagcgaaaa taagggtgat tacaaaaaga tgatatataa cttgctgccc 1860 ggcccgaata aaatgatccc aaaggtattc ctctcctcaa aaacaggagt ggagacctac 1920 aagcccagcg catatattct tgaagggtac aaacaaaaca agcatctgaa aagttctaag 1980 gactttgata tcactttctg tcacgacttg attgattatt ttaaaaattg catagccatc 2040 catccggagt ggaagaactt cggctttgac ttcagcgata cctccacata cgaagacatt 2100 tcaggttttt atcgcgaggt tgaactgcag ggctacaaaa tcgattggac ctatattagc 2160 gagaaggaca tagatctcct tcaggaaaaa ggacaactgt acttgttcca gatctataat 2220 aaggacttta gtaaaaagtc tactgggaac gataatctgc acaccatgta cctcaaaaac 2280 cttttcagcg aggaaaatct gaaggacatt gtcttgaaac tgaacggcga ggctgaaatc 2340 tttttccgga agtcctcaat taaaaatcct ataatccata agaaaggtag cattctcgtg 2400 aaccgcacat atgaggccga agagaaggat cagtttggca atatccaaat tgtacggaaa 2460 accatacccg aaaacatcta ccaggagctt tataagtact tcaatgacaa aagtgataag 2520 gaactgtctg acgaggcagc caaattgaag aacgtggttg gacaccatga agctgccact 2580 aatattgtca aagattatcg ctacacctat gacaagtact ttctgcacat gccgatcaca 2640 attaacttca aagcaaataa gaccagcttt ataaacgatc ggattctcca gtatattgcc 2700 aaagagaaga atcttcatgt gatcgggatt gaccgcggcg aacggaacct gatatacgta 2760 tccgtgatcg atacttgtgg taatattgtt gagcaaaaat cattcaacat cgtcaatggc 2820 tatgactacc agattaagtt gaaacagcaa gaaggagctc gccagatagc ccggaaggag 2880 tggaaggaaa tcgggaaaat taaggagatc aaagaaggct atctgagcct cgtgattcac 2940 gagataagta agatggtaat caaatacaac gcaattatcg ccatggaaga tctttcttat 3000 ggttttaaga aaggccgctt caaggtggag cggcaagttt accagaaatt tgaaaccatg 3060 ctgattaata agttgaacta tctggtcttc aaagacataa gcatcacaga gaatggaggg 3120 ctccttaagg gctaccagct gacctatatt ccagataaat tgaagaacgt gggtcatcaa 3180 tgcggctgta tcttttacgt acccgctgcc tatacttcca aaattgaccc gaccacagga 3240 ttcgtgaata tatttaagtt caaagatctg accgttgacg caaagcgcga atttatcaaa 3300 aagttcgatt caattcggta cgacagcgag aaaaagctct tttgcttcac ttttgattat 3360 aacaatttca tcacccagaa cacagtcatg agtaaatcta gctggtccgt gtacacctat 3420 ggggtacgca ttaagcggcg ctttgtgaat ggccggttct caaacgaaag cgacactata 3480 gatatcacca aagacatgga gaagacactt gaaatgaccg atattaattg gcgcgacggt 3540 cacgatctgc ggcaggacat cattgattac gagatagttc aacatatctt tgaaattttc 3600 cgcttgactg tccagatgcg gaacagtctg tctgagctcg aagaccgcga ttatgaccgg 3660 cttatcagcc ctgtgctgaa tgagaacaat attttttacg attccgccaa agctggcgac 3720 gccttgccca aggatgcaga cgccaacgga gcttattgta tagccctgaa agggctctac 3780 gaaatcaagc agattaccga gaattggaaa gaagatggca agttctcacg cgacaaactt 3840 aagatcagca acaaagattg gtttgacttc attcaaaata agcggtatct gggcggctcc 3900 cctgctgcta aacgtgttaa gcttgatggg ggtagcccgg cagccaagag agtcaaactc 3960 gacggcggct ccccagcggc aaaaagggtg aaactagacg ggggtagccc cgccgcgaag 4020 cgtgtaaagc tggatggagg atcgcctgcg gctaagcgag tcaaattaga cggtgggtca 4080 ccggctgcaa agcgcgtcaa attggatgct agcggcagcc accaccacca ccaccactga 4140 4140 <210> 21 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> HPRT1 <400> 21 ggttaaagat ggttaaatga t 21 <110> G+FLAS Life Sciences <120> Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof <130> SP20-0125KR <160> 21 <170> KoPatentIn 3.0 <210> 1 <211> 1330 < 212> PRT <213> Artificial Sequence <220> <223> mgCas12a-1 <400> 1 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg 20 25 30 Gly Ser Met Asn Asn Gly Thr Asn Asn Phe Gln Asn Phe Ile Gly Ile 35 40 45 Ser Ser Leu Gln Lys Thr Leu Arg Asn Ala Leu Ile Pro Thr Glu Thr 50 55 60 Thr Gln Gln Phe Ile Val Lys Asn Gly Ile Ile Lys Glu Asp Glu Leu 65 70 75 80 Arg Gly Glu Asn Arg Gln Ile Leu Lys Asp Ile Met Asp Asp Tyr Tyr 85 90 95 Arg Gly Phe Ile Ser Glu Thr Leu Ser Ser Ile Asp Asp Ile Asp Trp 100 105 110 Thr Ser Leu Phe Glu Lys Met Glu Ile Gln Leu Lys Asn Gly Asp Asn 115 120 125 Lys Asp Thr Leu Ile Lys Glu Gln Ala Glu Lys Arg Lys Ala I le Tyr 130 135 140 Lys Lys Phe Ala Asp Asp Asp Arg Phe Lys Asn Met Phe Ser Ala Lys 145 150 155 160 Leu Ile Ser Asp Ile Leu Pro Glu Phe Val Ile His Asn Asn Asn Asn Tyr 165 170 175 Ser Ala Ser Glu Lys Glu Glu Lys Thr Gln Val Ile Lys Leu Phe Ser 180 185 190 Arg Phe Ala Thr Ser Phe Lys Asp Tyr Phe Lys Asn Arg Ala Asn Cys 195 200 205 Phe Ser Ala Asp Asp Ile Ser Ser Ser Ser Cys His Arg Ile Val Asn 210 215 220 Asp Asn Ala Glu Ile Phe Phe Ser Asn Ala Leu Val Tyr Arg Arg Ile 225 230 235 240 Val Lys Asn Leu Ser Asn Asp Asp Ile Asn Lys Ile Ser Gly Asp Ile 245 250 255 Lys Asp Ser Leu Lys Glu Met Ser Leu Glu Glu Ile Tyr Ser Tyr Glu 260 265 270 Lys Tyr Gly Glu Phe Ile Thr Gln Glu Gly Ile S er Phe Tyr Asn Asp 275 280 285 Ile Cys Gly Lys Val Asn Ser Phe Met Asn Leu Tyr Cys Gln Lys Asn 290 295 300 Lys Glu Asn Lys Asn Leu Tyr Lys Leu Arg Lys Leu His Lys Gln Ile 305 310 315 320 Leu Cys Ile Ala Asp Thr Ser Tyr Glu Val Pro Tyr Lys Phe Glu Ser 325 330 335 Asp Glu Glu Val Tyr Gln Ser Val Asn Gly Phe Leu Asp Asn Ile Ser 340 345 350 Ser Lys His Ile Val Glu Arg Leu Arg Lys Ile Gly Asp Asn Tyr Asn 355 360 365 Gly Tyr Asn Leu Asp Lys Ile Tyr Ile Val Ser Lys Phe Tyr Glu Ser 370 375 380 Val Ser Gln Lys Thr Tyr Arg Asp Trp Glu Thr Ile Asn Thr Ala Leu 385 390 395 400 Glu Ile His Tyr Asn Asn Ile Leu Pro Gly Asn Gly Lys Ser Lys Ala 405 410 415 Asp Lys Val Lys Lys Ala Val Lys A sn Asp Leu Gln Lys Ser Ile Thr 420 425 430 Glu Ile Asn Glu Leu Val Ser Asn Tyr Lys Leu Cys Pro Asp Asp Asn 435 440 445 Ile Lys Ala Glu Thr Tyr Ile His Glu Ile Ser His Ile Leu Asn Asn 450 455 460 Phe Glu Ala Gln Glu Leu Lys Tyr Asn Pro Glu Ile His Leu Val Glu 465 470 475 480 Ser Glu Leu Lys Ala Ser Glu Leu Lys Asn Val Leu Asp Val Ile Met 485 490 495 Asn Ala Phe His Trp Cys Ser Val Phe Met Thr Glu Glu Leu Val Asp 500 505 510 Lys Asp Asn Asn Phe Tyr Ala Glu Leu Glu Glu Ile Tyr Asp Glu Ile 515 520 525 Tyr Thr Val Ile Ser Leu Tyr Asn Leu Val Arg Asn Tyr Val Thr Gln 530 535 540 Lys Pro Tyr Ser Thr Lys Lys Ile Lys Leu Asn Phe Gly Ile Pro Thr 545 550 555 560 Leu Ala Asp Gly Trp S er Lys Ser Lys Glu Tyr Ser Asn Asn Ala Ile 565 570 575 Ile Leu Met Arg Asp Asn Leu Tyr Tyr Leu Gly Ile Phe Asn Ala Lys 580 585 590 Asn Lys Pro Asp Lys Lys Ile Ile Glu Gly Asn Thr Ser Glu Asn Lys 595 600 605 Gly Asp Tyr Lys Lys Met Ile Tyr Asn Leu Leu Pro Gly Pro Asn Lys 610 615 620 Met Ile Pro Lys Val Phe Leu Ser Ser Lys Thr Gly Val Glu Thr Tyr 625 630 635 640 Lys Pro Ser Ala Tyr Ile Leu Glu Gly Tyr Lys Gln Asn Lys His Leu 645 650 655 Lys Ser Ser Lys Asp Phe Asp Ile Thr Phe Cys His Asp Leu Ile Asp 660 665 670 Tyr Phe Lys Asn Cys Ile Ala Ile His Pro Glu Trp Lys Asn Phe Gly 675 680 685 Phe Asp Phe Ser Asp Thr Ser Thr Tyr Glu Asp Ile Ser Gly Phe Tyr 690 695 700 Arg Glu Val Glu Leu Gln Gly T yr Lys Ile Asp Trp Thr Tyr Ile Ser 705 710 715 720 Glu Lys Asp Ile Asp Leu Leu Gln Glu Lys Gly Gln Leu Tyr Leu Phe 725 730 735 Gln Ile Tyr Asn Lys Asp Phe Ser Lys Lys Ser Thr Gly Asn Asp Asn 740 745 750 Leu His Thr Met Tyr Leu Lys Asn Leu Phe Ser Glu Glu Asn Leu Lys 755 760 765 Asp Ile Val Leu Lys Leu Asn Gly Glu Ala Glu Ile Phe Phe Arg Lys 770 775 780 Ser Ser Ile Lys Asn Pro Ile Ile His Lys Lys Gly Ser Ile Leu Val 785 790 795 800 Asn Arg Thr Tyr Glu Ala Glu Glu Lys Asp Gln Phe Gly Asn Ile Gln 805 810 815 Ile Val Arg Lys Thr Ile Pro Glu Asn Ile Tyr Gln Glu Leu Tyr Lys 820 825 830 Tyr Phe Asn Asp Lys Ser Asp Lys Glu Leu Ser Asp Glu Ala Ala Lys 835 840 845 Leu Lys Asn Val V al Gly His Glu Ala Ala Thr Asn Ile Val Lys 850 855 860 Asp Tyr Arg Tyr Thr Tyr Asp Lys Tyr Phe Leu His Met Pro Ile Thr 865 870 875 880 Ile Asn Phe Lys Ala Asn Lys Thr Ser Phe Ile Asn Asp Arg Ile Leu 885 890 895 Gln Tyr Ile Ala Lys Glu Lys Asn Leu His Val Ile Gly Ile Asp Arg 900 905 910 Gly Glu Arg Asn Leu Ile Tyr Val Ser Val Ile Asp Thr Cys Gly Asn 915 920 925 Ile Val Glu Gln Lys Ser Phe Asn Ile Val Asn Gly Tyr Asp Tyr Gln 930 935 940 Ile Lys Leu Lys Gln Gln Glu Gly Ala Arg Gln Ile Ala Arg Lys Glu 945 950 955 960 Trp Lys Glu Ile Gly Lys Ile Lys Glu Ile Lys Glu Gly Tyr Leu Ser 965 970 975 Leu Val Ile His Glu Ile Ser Lys Met Val Ile Lys Tyr Asn Ala Ile 980 985 990 Ile A la Met Glu Asp Leu Ser Tyr Gly Phe Lys Lys Gly Arg Phe Lys 995 1000 1005 Val Glu Arg Gln Val Tyr Gln Lys Phe Glu Thr Met Leu Ile Asn Lys 1010 1015 1020 Leu Asn Tyr Leu Val Phe Lys Asp Ile Ser Ile Thr Glu Asn Gly Gly 1025 1030 1035 1040 Leu Leu Lys Gly Tyr Gln Leu Thr Tyr Ile Pro Asp Lys Leu Lys Asn 1045 1050 1055 Val Gly His Gln Cys Gly Cys Ile Phe Tyr Val Pro Ala Ala Tyr Thr 1060 1065 1070 Ser Lys Ile Asp Pro Thr Thr Gly Phe Val Asn Ile Phe Lys Phe Lys 1075 1080 1085 Asp Leu Thr Val Asp Ala Lys Arg Glu Phe Ile Lys Lys Phe Asp Ser 1090 1095 1100 Ile Arg Tyr Asp Ser Glu Lys Lys Leu Phe Cys Phe Thr Phe Asp Tyr 1105 1110 1115 1120 Asn Asn Phe Ile Thr Gln Asn Thr Val Met Ser Lys Ser Ser Trp Ser 1125 1130 1135 Val Tyr Thr Tyr Gly Val Arg Ile Lys Arg Arg Phe Val Asn Gly Arg 1140 1145 1150 Phe Ser Asn Glu Ser Asp Thr Ile Asp Ile Thr Lys Asp Met Glu Lys 1155 1160 1165 Thr Leu Glu Met Thr Asp Ile Asn Trp Arg Asp Gly His Asp Leu Arg 1170 1175 1180 Gln Asp Ile Ile Asp Tyr Glu Ile Val Gln His Ile Phe Glu Ile Phe 1185 1190 1195 1200 Arg Leu Thr Val Gln Met Arg Asn Ser Leu Ser Glu Leu Glu Asp Arg 1205 1210 1215 Asp Tyr Asp Arg Leu Ile Ser Pro Val Leu Asn Glu Asn Asn Ile Phe 1220 1225 1230 Tyr Asp Ser Ala Lys Ala Gly Asp Ala Leu Pro Lys Asp Ala Asp Ala 1235 1240 1245 Asn Gly Ala Tyr Cys Ile Ala Leu Lys Gly Leu Tyr Glu Ile Lys Gln 1250 1255 1260 Ile Thr Glu Asn Trp Lys Glu Asp Gly Lys Phe Ser Arg Asp Lys Leu 1265 1270 1275 1280 Lys Ile Ser Asn Lys Asp Trp Phe Asp Phe Ile Gln Asn Lys Arg Tyr 1285 1290 1295 Leu Ala Ala Ala Leu Glu Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 1300 1305 1310 Gln Ala Lys Lys Lys Lys Ser Thr Pro Pro Pro Pro Pro Leu Arg Ser 1315 1320 1325 Gly Cys 1330 <210> 2 <211> 3993 <212> DNA <213> Artificial Sequence <220> <223> mgCas12a-1 <400> 2 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atggctagca tgactggtgg acagcaaatg ggtcgcggat ccatgaacaa tggcaccaac 120 aatttccaga actttatcgg aattagcagt ctgcaaaaga ctctccggaa tgcccttata 180 cccaccgaga caacccag ca gttcatcgtg aaaaacggga ttatcaagga agacgagctg 240 cgcggcgaaa atcggcaaat tttgaaagat ataatggacg attattaccg cggttttatc 300 tctgagactc tgagctccat tgacgatatc gactggacct cactcttcga aaagatggag 360 attcagctta aaaacggcga taataaggac acactgataa aagaacaggc tgagaagcgg 420 aaagccatct ataagaaatt tgcagatgac gatcgcttca agaacatgtt tagcgccaaa 480 ttgattagtg acatcctgcc ggaattcgtt attcacaata acaattactc tgctagcgag 540 aaggaagaga aaacccaagt cataaagctc ttttcccggt tcgccacttc atttaaagat 600 tatttcaaga accgcgcaaa ttgctttagc gccgacgata tcagttctag ctcctgtcat 660 cggattgtga acgacaatgc tgaaatcttc ttttcaaacg cccttgtata ccgccggatt 720 gtgaaaaatc tgagcaacga tgacataaat aagatcagtg gagatattaa agactctttg 780 aaggagatga gcctggaaga gatctattcc tacgaaaaat atggggagtt cattacccag 840 gaaggcatat cattttacaa cgatatctgc ggtaaggtta atagcttcat gaacctctat 900 tgtcagaaaa ataaggagaa caaaaatctt tacaagctgc gcaaattgca caagcaaatt 960 ctgtgcatcg cagacacaag ttatgaagtc ccttacaaat ttgagtctga tgaagaggtg 1020 tatcagagcg taaacggctt cctcgacaat atttc ctcaa agcatatagt ggaacggctt 1080 cgcaaaatcg gagataacta caatgggtat aacctggaca agatttacat cgttagcaaa 1140 ttttatgaga gtgtctctca gaagacctac cgggattggg aaactattaa taccgccttg 1200 gagatacact ataacaatat cctgcccggc aacggtaaaa gcaaggctga caaagtgaag 1260 aaagccgtaa agaatgatct ccaaaaatcc attacagaaa tcaacgagct tgtgtcaaat 1320 tacaagctgt gtccggacga taacattaaa gcagaaacct atatacatga gatcagccac 1380 attttgaata acttcgaagc ccaggagctg aagtacaatc cagaaatcca tctcgttgag 1440 agtgaactta aagcttctga gctgaagaac gtcttggacg tgattatgaa tgcctttcac 1500 tggtgcagcg tattcatgac tgaagagctg gtggataaag acaacaattt ttatgcagaa 1560 ctcgaggaaa tatacgatga gatctatacc gttatttccc tttacaacct ggtccgcaat 1620 tatgtgacac agaagcccta ctcaaccaaa aagatcaaat tgaacttcgg cattccgact 1680 ctggccgacg gatggagcaa gagtaaagaa tattctaata acgctataat cctcatgcgg 1740 gataatcttt actatctggg gatttttaac gccaagaata aacctgacaa gaaaatcatt 1800 gagggcaaca ccagcgaaaa taagggtgat tacaaaaaga tgatatataa cttgctgccc 1860 ggcccgaata aaatgatccc aaaggtattc ctctcctcaa aaacaggagt ggagacctac 1920 aagcccagcg catatattct tgaagggtac aaacaaaaca agcatctgaa aagttctaag 1980 gactttgata tcactttctg tcacgacttg attgattatt ttaaaaattg catagccatc 2040 catccggagt ggaagaactt cggctttgac ttcagcgata cctccacata cgaagacatt 2100 tcaggttttt atcgcgaggt tgaactgcag ggctacaaaa tcgattggac ctatattagc 2160 gagaaggaca tagatctcct tcaggaaaaa ggacaactgt acttgttcca gatctataat 2220 aaggacttta gtaaaaagtc tactgggaac gataatctgc acaccatgta cctcaaaaac 2280 cttttcagcg aggaaaatct gaaggacatt gtcttgaaac tgaacggcga ggctgaaatc 2340 tttttccgga agtcctcaat taaaaatcct ataatccata agaaaggtag cattctcgtg 2400 aaccgcacat atgaggccga agagaaggat cagtttggca atatccaaat tgtacggaaa 2460 accatacccg aaaacatcta ccaggagctt tataagtact tcaatgacaa aagtgataag 2520 gaactgtctg acgaggcagc caaattgaag aacgtggttg gacaccatga agctgccact 2580 aatattgtca aagattatcg ctacacctat gacaagtact ttctgcacat gccgatcaca 2640 attaacttca aagcaaataa gaccagcttt ataaacgatc ggattctcca gtatattgcc 2700 aaagagaaga atcttcatgt gatcgggatt gaccgcggcg aacgga acct gatatacgta 2760 tccgtgatcg atacttgtgg taatattgtt gagcaaaaat cattcaacat cgtcaatggc 2820 tatgactacc agattaagtt gaaacagcaa gaaggagctc gccagatagc ccggaaggag 2880 tggaaggaaa tcgggaaaat taaggagatc aaagaaggct atctgagcct cgtgattcac 2940 gagataagta agatggtaat caaatacaac gcaattatcg ccatggaaga tctttcttat 3000 ggttttaaga aaggccgctt caaggtggag cggcaagttt accagaaatt tgaaaccatg 3060 ctgattaata agttgaacta tctggtcttc aaagacataa gcatcacaga gaatggaggg 3120 ctccttaagg gctaccagct gacctatatt ccagataaat tgaagaacgt gggtcatcaa 3180 tgcggctgta tcttttacgt acccgctgcc tatacttcca aaattgaccc gaccacagga 3240 ttcgtgaata tatttaagtt caaagatctg accgttgacg caaagcgcga atttatcaaa 3300 aagttcgatt caattcggta cgacagcgag aaaaagctct tttgcttcac ttttgattat 3360 aacaatttca tcacccagaa cacagtcatg agtaaatcta gctggtccgt gtacacctat 3420 ggggtacgca ttaagcggcg ctttgtgaat ggccggttct caaacgaaag cgacactata 3480 gatatcacca aagacatgga gaagacactt gaaatgaccg atattaattg gcgcgacggt 3540 cacgatctgc ggcaggacat cattgattac gagatagttc aacatatctt t gaaattttc 3600 cgcttgactg tccagatgcg gaacagtctg tctgagctcg aagaccgcga ttatgaccgg 3660 cttatcagcc ctgtgctgaa tgagaacaat attttttacg attccgccaa agctggcgac 3720 gccttgccca aggatgcaga cgccaacgga gcttattgta tagccctgaa agggctctac 3780 gaaatcaagc agattaccga gaattggaaa gaagatggca agttctcacg cgacaaactt 3840 aagatcagca acaaagattg gtttgacttc attcaaaata agcggtatct ggcggccgca 3900 ctcgagaaaa ggccggcggc cacgaaaaag gccggccagg caaaaaagaa aaagtcgaca 3960 ccaccaccac caccactgag atccggctgc taa 3993 < 210> 3 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> myc-NLS <400> 3 ccggcagcca agagagtcaa actcgac 27 <210> 4 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> myc-NLS <400> 4 Pro Ala Ala Lys Arg Val Lys Leu Asp 1 5 <210> 5 <211> 130 <212> DNA <213> Artificial Sequence <220> <223> Core region < 400> 5 agccaagaga gtcaaactcg acggcggctc cccagcggca aaaagggtga aactagacgg 60 gggtagcccc gccgcgaagc gtgtaaagct ggatggagga tcgcctgcgg DNA ctaagcgagt 120 caaattagac 130 <212> 6 <211> 13> Artificial Sequence <220> <223> extension primer_forward <400> 6 ttgacttcat tcaaaataag cggtatctgg gcggctcccc tgctgctaaa cgtgttaagc 60 ttgatggggg tagcccggca gccaagag220 tcaaactcg 99 <212> DNA <211> 100 Artificial Sequence > extension primer_reverse <400> 7 agccggatct cagtggtggt ggtggtggtg gctgccgcta gcatccaatt tgacgcgctt 60 tgcagccggt gacccaccgt ctaatttgac tcgcttagcc 100 mgCas <212> 1379 <212> PRT <213 8 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg 20 25 30 Gly Ser Met Asn Asn Gly Thr Asn Asn Phe Gln Asn Phe Ile Gly Ile 35 40 45 Ser Ser Leu Gln Lys Thr Leu Arg Asn Ala Leu Ile Pro Thr Glu Thr 50 55 60 Thr Gln Gln Phe Ile Val Lys Asn Gly Ile Ile Lys Glu Asp Glu Leu 65 70 75 80 Arg Gly Glu Asn Arg Gln Ile Leu Lys Asp Ile Met Asp Asp Tyr Tyr 85 90 95 Arg Gly Phe Ile Ser Glu Thr Leu Ser Ser Ile Asp Asp Ile Asp Trp 100 105 110 Thr Ser Leu Phe Glu Lys Met Glu Ile Gln Leu Lys Asn Gly Asp Asn 115 120 125 Lys Asp Thr Leu Ile Lys Glu Gln Ala Glu Lys Arg Lys Ala Ile Tyr 130 135 140 Lys Lys Phe Ala Asp Asp Asp Arg Phe Lys Asn Met Phe Ser Ala Lys 145 150 155 160 Leu Ile Ser Asp Ile Leu Pro Glu Phe Val Ile His Asn Asn Asn Tyr 165 170 175 Ser Ala Ser Glu Lys Glu Glu Lys Thr Gln Val Ile Lys Leu Phe Ser 180 185 190 Arg Phe Ala Thr Ser Phe Lys Asp Tyr Phe Lys Asn Arg Ala Asn Cys 195 200 205 Phe Ser Ala Asp Asp Ile Ser Ser Ser Ser Cys His Arg Ile Val Asn 210 215 220 Asp Asn Ala Glu Ile Phe Phe Ser Asn Ala Leu Val Tyr Arg Arg Ile 225 230 235 240 Val Lys Asn Leu Ser Asn Asp Asp Ile Asn Lys Ile Ser Gly Asp Ile 245 250 255 Lys Asp Ser Leu Lys Glu Met Ser Leu Glu Glu Ile Tyr Ser Tyr Glu 260 265 270 Lys Tyr Gly Glu Phe Ile Thr Gln Glu Gly Ile Ser Phe Tyr Asn Asp 275 280 285 Ile Cys Gly Lys Val Asn Ser Phe Met Asn Leu Tyr Cys Gln Lys Asn 290 295 300 Lys Glu Asn Lys Asn Leu Tyr Lys Leu Arg Lys Leu His Lys Gln Ile 305 310 315 320 Leu Cys Ile Ala Asp Thr Ser Tyr Glu Val Pro Tyr Lys Phe Glu Ser 325 330 335 Asp Glu Glu Val Tyr Gln Ser Val Asn Gly Phe Leu Asp Asn Ile Ser 340 345 350 Ser Lys His Ile Val Glu Arg Leu Arg Lys Ile Gly Asp Asn Tyr Asn 355 360 365 Gly Tyr Asn Leu Asp Lys Ile Tyr Ile Val Ser Lys Phe Tyr Glu Ser 370 375 380 Val Ser Gln Lys Thr Tyr Arg Asp Trp Glu Thr Ile Asn Thr Ala Leu 385 390 395 400 Glu Ile His Tyr Asn Asn Ile Leu Pro Gly Asn Gly Lys Ser Lys Ala 405 410 415 Asp Lys Val Lys Lys Ala Val Lys Asn Asp Leu Gln Lys Ser Ile Thr 420 425 430 Glu Ile Asn Glu Leu Val Ser Asn Tyr Lys Leu Cys Pro Asp Asp Asn 435 440 445 Ile Lys Ala Glu Thr Tyr Ile His Glu Ile Ser His Ile Leu Asn Asn 450 455 460 Phe Glu Ala Gln Glu Leu Lys Tyr Asn Pro Glu Ile His Leu Val Glu 465 470 475 480 Ser Glu Leu Lys Ala Ser Glu Leu Lys Asn Val Leu Asp Val Ile Met 485 490 495 Asn Ala Phe His Trp Cys Ser Val Phe Met Thr Glu Glu Leu Val Asp 500 505 510 Lys Asp Asn Asn Phe Tyr Ala Glu Leu Glu Glu Ile Tyr Asp Glu Ile 515 520 525 Tyr Thr Val Ile Ser Leu Tyr Asn Leu Val Arg Asn Tyr Val Thr Gln 530 535 540 Lys Pro Tyr Ser Thr Lys Lys Ile Lys Leu Asn Phe Gly Ile Pro Thr 545 550 555 560 Leu Ala Asp Gly Trp Ser Lys Ser Lys Glu Tyr Ser Asn Asn Ala Ile 565 570 575 Ile Leu Met Arg Asp Asn Leu Tyr Tyr Leu Gly Ile Phe Asn Ala Lys 580 585 590 Asn Lys Pro Asp Lys Lys Ile Ile Glu Gly Asn Thr Ser Glu Asn Lys 595 600 605 Gly Asp Tyr Lys Lys Met Ile Tyr Asn Leu Leu Pro Gly Pro Asn Lys 610 615 620 Met Ile Pro Lys Val Phe Leu Ser Ser Lys Thr Gly Val Glu Thr Tyr 625 630 635 640 Lys Pro Ser Ala Tyr Ile Leu Glu Gly Tyr Lys Gln Asn Lys His Leu 645 650 655 Lys Ser Ser Lys Asp Phe Asp Ile Thr Phe Cys His Asp Leu Ile Asp 660 665 670 Tyr Phe Lys Asn Cys Ile Ala Ile His Pro Glu Trp Lys Asn Phe Gly 675 680 685 Phe Asp Phe Ser Asp Thr Ser Thr Tyr Glu Asp Ile Ser Gly Phe Tyr 690 695 700 Arg Glu Val Glu Leu Gln Gly Tyr Lys Ile Asp Trp Thr Tyr Ile Ser 705 710 715 720 Glu Lys Asp Ile Asp Leu Leu Gln Glu Lys Gly Gln Leu Tyr Leu Phe 725 730 735 Gln Ile Tyr Asn Lys Asp Phe Ser Lys Lys Ser Thr Gly Asn Asp Asn 740 745 750 Leu His Thr Met Tyr Leu Lys Asn Leu Phe Ser Glu Glu Asn Leu Lys 755 760 765 Asp Ile Val Leu Lys Leu Asn Gly Glu Ala Glu Ile Phe Phe Arg Lys 770 775 780 Ser Ser Ile Lys Asn Pro Ile Ile His Lys Lys Lys Gly Ser Ile Leu Val 785 790 795 800 Asn Arg Thr Tyr Glu Ala Glu Glu Lys Asp Gln Phe Gly Asn Ile Gln 805 810 815 Ile Val Arg Lys Thr Ile Pro Glu Asn Ile Tyr Gln Glu Leu Tyr Lys 820 825 830 Tyr Phe Asn Asp Lys Ser Asp Lys Glu Leu Ser Asp Glu Ala Ala Lys 835 840 845 Leu Lys Asn Val Val Gly His His Glu Ala Ala Thr Asn Ile Val Lys 850 855 860 Asp Tyr Arg Tyr Thr Tyr Asp Lys Tyr Phe Leu His Met Pro Ile Thr 865 870 875 880 Ile Asn Phe Lys Ala Asn Lys Thr Ser Phe Ile Asn Asp Arg Ile Leu 885 890 895 Gln Tyr Ile Ala Lys Glu Lys Asn Leu His Val Ile Gly Ile Asp Arg 900 905 910 Gly Glu Arg Asn Leu Ile Tyr Val Ser Val Ile Asp Thr Cys Gly Asn 915 920 925 Ile Val Glu Gln Lys Ser Phe Asn Ile Val Asn Gly Tyr Asp Tyr Gln 930 935 940 Ile Lys Leu Lys Gln Gln Glu Gly Ala Arg Gln Ile Ala Arg Lys Glu 945 950 955 960 Trp Lys Glu Ile Gly Lys Ile Lys Glu Ile Lys Glu Gly Tyr Leu Ser 965 970 975 Leu Val Ile His Glu Ile Ser Lys Met Val Ile Lys Tyr Asn Ala Ile 980 985 990 Ile Ala Met Glu Asp Leu Ser Tyr Gly Phe Lys Lys Gly Arg Phe Lys 995 1000 1005 Val Glu Arg Gln Val Tyr Gln Lys Phe Glu Thr Met Leu Ile Asn Lys 1010 1015 1020 Leu Asn Tyr Leu Val Phe Lys Asp Ile Ser Ile Thr Glu Asn Gly Gly 1025 1030 1035 1040 Leu Leu Lys Gly Tyr Gln Leu Thr Tyr Ile Pro Asp Lys Leu Lys Asn 1045 1050 1055 Val Gly His Gln Cys Gly Cys Ile Phe Tyr Val Pro Ala Ala Tyr Thr 1060 1065 1070 Ser Lys Ile Asp Pro Thr Thr Gly Phe Val Asn Ile Phe Lys Phe Lys 1075 1080 1085 Asp Leu Thr Val Asp Ala Lys Arg Glu Phe Ile Lys Lys Phe Asp Ser 1090 1095 1100 Ile Arg Tyr Asp Ser Glu Lys Lys Leu Phe Cys Phe Thr Phe Asp Tyr 1105 1110 1115 1120 Asn Asn Phe Ile Thr Gln Asn Thr Val Met Ser Lys Ser Ser Trp Ser 1125 1130 1135 Val Tyr Thr Tyr Gly Val Arg Ile Lys Arg Arg Phe Val Asn Gly Arg 1140 1145 1150 Phe Ser Asn Glu Ser Asp Thr Ile Asp Ile Thr Lys Asp Met Glu Lys 1155 1160 1165 Thr Leu Glu Met Thr Asp Ile Asn Trp Arg Asp Gly His Asp Leu Arg 1170 1175 1180 Gln Asp Ile Ile Asp Tyr Glu Ile Val Gln His Ile Phe Glu Ile Phe 1185 1190 1195 1200 Arg Leu Thr Val Gln Met Arg Asn Ser Leu Ser Glu Leu Glu Asp Arg 1205 1210 1215 Asp Tyr Asp Arg Leu Ile Ser Pro Val Leu Asn Glu Asn Asn Ile Phe 1220 1225 1230 Tyr Asp Ser Ala Lys Ala Gly Asp Ala Leu Pro Lys Asp Ala Asp Ala 1235 1240 1245 Asn Gly Ala Tyr Cys Ile Ala Leu Lys Gly Leu Tyr Glu Ile Lys Gln 1250 1255 1260 Ile Thr Glu Asn Trp Lys Glu Asp Gly Lys Phe Ser Arg Asp Lys Leu 1265 1270 1275 1280 Lys Ile Ser Asn Lys Asp Trp Trp Phe Asp Phe Ile Phe Asp Phe Gln Asn Lys Arg Tyr 1285 1290 1295 Leu Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser 1300 1305 1310 Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Gly Ser Pro Ala Ala Lys 1315 1320 1325 Arg Val Lys Leu Asp Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu 1330 1335 1340 Asp Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser 1345 1350 1355 1360 Pro Ala Ala Lys Arg Val Lys Leu Asp Ala Ser Gly Ser His His His 1365 1370 1375 His His His <210> 9 <211> 4140 <212> DNA <213> Artificial Sequence <220> <223> mgCas12a-1-6XNLS <400> 9 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atggctagca tgactggtgg acagcaaatg ggtcgcggat ccatgaacaa tggcaccaac 120 aatttccaga actttatcgg aattagcagt ctgcaaaaga ctctccggaa tgcccttata 180 cccaccgaga caacccagca gttcatcgtg aaaaacggga ttatcaagga agacgagctg 240 cgcggcgaaa atcggcaaat tttgaaagat ataatggacg attattaccg cggttttatc 300 tctgagactc tgagctccat tgacgatatc gactggacct cactcttcga aaagatggag 360 attcagctta aaaacggcga taataaggac acactgataa aagaacaggc tgagaagcgg 420 aaagccatct ataagaaatt tgcagatgac gatcgcttca agaacatgtt tagcgccaaa 480 ttgattagtg acatcctgcc ggaattcgtt attcacaata acaattactc tgctagcgag 540 aaggaagaga aaacccaagt cataaagctc ttttcccggt tcgccacttc atttaaagat 600 tatttcaaga accgcgcaaa ttgctttagc gccgacgata tcagttctag ctcctgtcat 660 cggattgtga acgacaatgc tgaaatcttc ttttcaaacg cccttgtata ccgccggatt 720 gtgaaaaatc tgagcaacga tgacataaat aagatcagtg gagatattaa agactctttg 780 aaggagatga gcctggaaga gatctattcc tacgaaaaat atggggagtt cattacccag 840 gaaggcatat cattttacaa cgatatctgc ggtaaggtta atagcttcat gaacctctat 900 tgtcagaaaa ataaggagaa caaaaatctt tacaagctgc gcaaattgca caagcaaatt 960 ctgtgcatcg cagacacaag ttatgaagtc ccttacaaat ttgagtctga tgaagaggtg 1020 tatcagagcg taaacggctt cctcgacaat atttcctcaa agcatatagt ggaacggctt 1080 cgcaaaatcg gagataacta caatgggtat aacctggaca agatttacat cgttagcaaa 1140 ttttatgaga gtgtctctca gaagacctac cgggattggg aaactattaa taccgccttg 1200 gagatacact ataacaatat cctgcccggc aacggtaaaa gcaaggctga caaagtgaag 1260 aaagccgtaa agaatgatct ccaaaaatcc attacagaaa tcaacgagct tgtgtcaaat 1320 tacaagctgt gtccggacga taacattaaa gcagaaacct atatacatga gatcagccac 1380 attttgaata acttcgaagc ccaggagctg aagtacaatc cagaaatcca tctcgttgag 1440 agtgaactta aagcttctga gctgaagaac gtcttggacg tgattatgaa tgcctttcac 1500 tggtgcagcg tattcatgac tgaagagctg gtggataaag acaacaattt ttatgcagaa 1560 ctcgaggaaa tatacgatga gatctatacc gttatttccc tttacaacct ggtccgcaat 1620 tatgtgacac agaagcccta ctcaaccaaa aagatcaaat tgaacttcgg cattccgact 1680 ctggccgacg gatggagcaa gagtaaagaa tattctaata acgctataat cctcatgcgg 1740 ga taatcttt actatctggg gatttttaac gccaagaata aacctgacaa gaaaatcatt 1800 gagggcaaca ccagcgaaaa taagggtgat tacaaaaaga tgatatataa cttgctgccc 1860 ggcccgaata aaatgatccc aaaggtattc ctctcctcaa aaacaggagt ggagacctac 1920 aagcccagcg catatattct tgaagggtac aaacaaaaca agcatctgaa aagttctaag 1980 gactttgata tcactttctg tcacgacttg attgattatt ttaaaaattg catagccatc 2040 catccggagt ggaagaactt cggctttgac ttcagcgata cctccacata cgaagacatt 2100 tcaggttttt atcgcgaggt tgaactgcag ggctacaaaa tcgattggac ctatattagc 2160 gagaaggaca tagatctcct tcaggaaaaa ggacaactgt acttgttcca gatctataat 2220 aaggacttta gtaaaaagtc tactgggaac gataatctgc acaccatgta cctcaaaaac 2280 cttttcagcg aggaaaatct gaaggacatt gtcttgaaac tgaacggcga ggctgaaatc 2340 tttttccgga agtcctcaat taaaaatcct ataatccata agaaaggtag cattctcgtg 2400 aaccgcacat atgaggccga agagaaggat cagtttggca atatccaaat tgtacggaaa 2460 accatacccg aaaacatcta ccaggagctt tataagtact tcaatgacaa aagtgataag 2520 gaactgtctg acgaggcagc caaattgaag aacgtggttg gacaccatga agctgccact 2580 aatattgt ca aagattatcg ctacacctat gacaagtact ttctgcacat gccgatcaca 2640 attaacttca aagcaaataa gaccagcttt ataaacgatc ggattctcca gtatattgcc 2700 aaagagaaga atcttcatgt gatcgggatt gaccgcggcg aacggaacct gatatacgta 2760 tccgtgatcg atacttgtgg taatattgtt gagcaaaaat cattcaacat cgtcaatggc 2820 tatgactacc agattaagtt gaaacagcaa gaaggagctc gccagatagc ccggaaggag 2880 tggaaggaaa tcgggaaaat taaggagatc aaagaaggct atctgagcct cgtgattcac 2940 gagataagta agatggtaat caaatacaac gcaattatcg ccatggaaga tctttcttat 3000 ggttttaaga aaggccgctt caaggtggag cggcaagttt accagaaatt tgaaaccatg 3060 ctgattaata agttgaacta tctggtcttc aaagacataa gcatcacaga gaatggaggg 3120 ctccttaagg gctaccagct gacctatatt ccagataaat tgaagaacgt gggtcatcaa 3180 tgcggctgta tcttttacgt acccgctgcc tatacttcca aaattgaccc gaccacagga 3240 ttcgtgaata tatttaagtt caaagatctg accgttgacg caaagcgcga atttatcaaa 3300 aagttcgatt caattcggta cgacagcgag aaaaagctct tttgcttcac ttttgattat 3360 aacaatttca tcacccagaa cacagtcatg agtaaatcta gctggtccgt gtacacctat 3420 ggggtacgca tta agcggcg ctttgtgaat ggccggttct caaacgaaag cgacactata 3480 gatatcacca aagacatgga gaagacactt gaaatgaccg atattaattg gcgcgacggt 3540 cacgatctgc ggcaggacat cattgattac gagatagttc aacatatctt tgaaattttc 3600 cgcttgactg tccagatgcg gaacagtctg tctgagctcg aagaccgcga ttatgaccgg 3660 cttatcagcc ctgtgctgaa tgagaacaat attttttacg attccgccaa agctggcgac 3720 gccttgccca aggatgcaga cgccaacgga gcttattgta tagccctgaa agggctctac 3780 gaaatcaagc agattaccga gaattggaaa gaagatggca agttctcacg cgacaaactt 3840 aagatcagca acaaagattg gtttgacttc attcaaaata agcggtatct gggcggctcc 3900 cctgctgcta aacgtgttaa gcttgatggg ggtagcccgg cagccaagag agtcaaactc 3960 gacggcggct ccccagcggc aaaaagggtg aaactagacg ggggtagccc cgccgcgaag 4020 cgtgtaaagc tggatggagg atcgcctgcg gctaagcgag tcaaattaga cggtgggtca 4080 ccggctgcaa agcgcgtcaa attggatgct agcggcagcc accaccacca ccaccactga 4140 4140 <210> 10 <211> 164 <212> DNA <213> Artificial Sequence <220> <223> insert1 <400> 10 gcgccaaatt gattagtgac atcctgccgg aattcgttat tcacaataac aattactctg 60 ctag cgagaa ggaagagaaa acccaagtca taaagctctt ttcccggttc gccacttcat 120 ttaaagatta tttccgcaac cgcgcaaatt gctttagcgc cgac 164 <210> 11 <211> 53 <212> DNA <213> 210 gcttagg acttag aatt gattag acttag aatt gattag acttag aatt 53 <220> <223> insert1_primer > 12 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> insert1_primer_reverse <400> 12 gtcggcgcta aagcaatttg cgcggttgcg gaaataatct ttaaatgaag tggc 54 <210> 13 <211> 1083 <212> DNA <213> Artificial Sequence <220> <223> insert2 <400> 13 cgcaaccgcg caaattgctt tagcgccgac gatatcagtt ctagctcctg tcatcggatt 60 gtgaacgaca atgctgaaat cttcttttca aacgcccttg tataccgccg gattgtgaaa 120 aatctgagca acgatgacat aaataagatc agtggagata ttaaagactc tttgaaggag 180 atgagcctgg aagagatcta ttcctacgaa aaatatgggg agttcattac ccaggaaggc 240 atatcatttt acaacgatat ctgcggtaag gttaatagct tcatgaacct ctattgtcag 300 aaaaataagg agaacaaaaa tctttacaag ctgcgcaaat tgcacaagca aattctgtgc 360 atcgcagaca caagttatga agtcccttac aaatttgagt ctgatgaaga g gtgtatcag 420 agcgtaaacg gcttcctcga caatatttcc tcaaagcata tagtggaacg gcttcgcaaa 480 atcggagata actacaatgg gtataacctg gacaagattt acatcgttag caaattttat 540 gagagtgtct ctcagaagac ctaccgggat tgggaaacta ttaataccgc cttggagata 600 cactataaca atatcctgcc cggcaacggt aaaagcaagg ctgacaaagt gaagaaagcc 660 gtaaagaatg atctccaaaa atccattaca gaaatcaacg agcttgtgtc aaattacaag 720 ctgtgtccgg acgataacat taaagcagaa acctatatac atgagatcag ccacattttg 780 aataacttcg aagcccagga gctgaagtac aatccagaaa tccatctcgt tgagagtgaa 840 cttaaagctt ctgagctgaa gaacgtcttg gacgtgatta tgaatgcctt tcactggtgc 900 agcgtattca tgactgaaga gctggtggat aaagacaaca atttttatgc agaactcgag 960 gaaatatacg atgagatcta taccgttatt tccctttaca acctggtccg caattatgtg 1020 acacagaagc cctactcaac caaaaagatc aaattgaact tcggcattcc gactctggcc 1080 cgc 1083 <210> 14 <211> 30 <212> DNA <213> Artificial Sequence <220 > <223> insert2_primer_forward <400> 14 cgcaaccgcg caaattgctt tagcgccgac 30 <210> 15 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> inserter t2_primer_reverse <400> 15 gcgggccaga gtcggaatgc cgaagttcaa 30 <210> 16 <211> 281 <212> DNA <213> Artificial Sequence <220> <223> insert3 <400> 16 ttgaacttcg gcattccgac t gg ttagacta gg t gattatatagat g cattatatagat t gattatatagat ccattatatta at agatagat t2_primer_reverse <400> 15 120 aaacctgaca agaaaatcat tgagggcaac accagcgaaa ataagggtga ttacaaaaag 180 atgatatata acttgctgcc cggcccgaat aaaatgatcc caaaggtatt cctctcctca 240 aaaacaggag tggagaccta caagcccagc gcatatattc t 281 <210> 17 <211> 50 <212> DNA <213> Artificial Sequence <220> <223> insert3_primer_forward <400> 17 ttgaacttcg gcattccgac tctggcccgc ggatggagca agagtaaaga 50 <210> 18 <211> 50 <212> DNA <213> Artificial Sequence <220> <223> insert3_primer_reverse <400> 18 agaatatatg cgctgggctt gtaggtctcc actcctgttt ttgaggagag 50 <210> <211> 1279212> PRT <213> Artificial Sequence <220> <223> opmgCas12a-1-6XNLS <400> 19 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg 20 25 30 Gly Ser Met Asn Asn Gly Thr Asn Asn Phe Gln Asn Phe Ile Gly Ile 35 40 45 Ser Ser Leu Gln Lys Thr Leu Arg Asn Ala Leu Ile Pro Thr Glu Thr 50 55 60 Thr Gln Gln Phe Ile Val Lys Asn Gly Ile Ile Lys Glu Asp Glu Leu 65 70 75 80 Arg Gly Glu Asn Arg Gln Ile Leu Lys Asp Ile Met Asp Asp Tyr Tyr 85 90 95 Arg Gly Phe Ile Ser Glu Thr Leu Ser Ser Ile Asp Asp Ile Asp Trp 100 105 110 Thr Ser Leu Phe Glu Lys Met Glu Ile Gln Leu Lys Asn Gly Asp Asn 115 120 125 Lys Asp Thr Leu Ile Lys Glu Gln Ala Glu Lys Arg Lys Ala Ile Tyr 130 135 140 Lys Lys Phe Ala Asp Asp Asp Arg Phe Lys Asn Met Phe Ser Ala Lys 145 150 155 160 Leu Ile Ser Asp Ile Leu Pro Glu Phe Val Ile His Asn Asn Asn Tyr 165 170 175 Ser Ala Ser Glu Lys Glu Glu Lys Thr Gln Val Ile Lys Leu Phe Ser 180 185 190 Arg Phe Ala Thr Ser Phe Lys Asp Tyr Phe Arg Asn Arg Ala Asn Cys 195 200 205 Phe Ser Ala Asp Asp Ile Ser Ser Ser Ser Cys His Arg Ile Val Asn 210 215 220 Asp Asn Ala Glu Ile Phe Phe Ser Asn Ala Leu Val Tyr Arg Arg Ile 225 230 235 240 Val Lys Asn Leu Ser Asn Asp Asp Ile Asn Lys Ile Ser Gly Asp Ile 245 250 255 Lys Asp Ser Leu Lys Glu Met Ser Leu Glu Glu Ile Tyr Ser Tyr Glu 260 265 270 Lys Tyr Gly Glu Phe Ile Thr Gln Glu Gly Ile Ser Phe Tyr Asn Asp 275 280 285 Ile Cys Gly Lys Val Asn Ser Phe Met Asn Leu Tyr Cys Gln Lys Asn 290 295 300 Lys Glu Asn Lys Asn Leu Tyr Lys Leu Arg Lys Leu His Lys Gln Ile 305 310 315 320 Leu Cys Ile Ala Asp Thr Ser Tyr Glu Val Pro Tyr Lys Phe Glu Ser 325 330 335 Asp Glu Glu Val Tyr Gln Ser Val Asn Gly Phe Leu Asp Asn Ile Ser 340 345 350 Ser Lys His Ile Val Glu Arg Leu Arg Lys Ile Gly Asp Asn Tyr Asn 355 360 365 Gly Tyr Asn Leu Asp Lys Ile Tyr Ile Val Ser Lys Phe Tyr Glu Ser 370 375 380 Val Ser Gln Lys Thr Tyr Arg Asp Trp Glu Thr Ile Asn Thr Ala Leu 385 390 395 400 Glu Ile His Tyr Asn Asn Ile Leu Pro Gly Asn Gly Lys Ser Lys Ala 405 410 415 Asp Lys Val Lys Lys Ala Val Lys Asn Asp Leu Gln Lys Ser Ile Thr 420 425 430 Glu Ile Asn Glu Leu Val Ser Asn Tyr Lys Leu Cys Pro Asp Asp Asn 435 440 445 Ile Lys Ala Glu Thr Tyr Ile His Glu Ile Ser His Ile Leu Asn Asn 450 455 460 Phe Glu Ala Gln Glu Leu Lys Tyr Asn Pro Glu Ile His Leu Val Glu 465 470 475 480 Ser Glu Leu Lys Ala Ser Glu Leu Lys Asn Val Leu Asp Val Ile Met 485 490 495 Asn Ala Phe His Trp Cys Ser Val Phe Met Thr Glu Glu Leu Val Asp 500 505 510 Lys Asp Asn Asn Phe Tyr Ala Glu Leu Glu Glu Ile Tyr Asp Glu Ile 515 520 525 Tyr Thr Val Ile Ser Leu Tyr Asn Leu Val Arg Asn Tyr Val Thr Gln 530 535 540 Lys Pro Tyr Ser Thr Lys Lys Ile Lys Leu Asn Phe Gly Ile Pro Thr 545 550 555 560 Leu Ala Arg Gly Trp Ser Lys Ser Lys Glu Tyr Ser Asn Asn Ala Ile 565 570 575 Ile Leu Met Arg Asp Asn Leu Tyr Tyr Leu Gly Ile Phe Asn Ala Lys 580 585 590 Asn Lys Pro Asp Lys Lys Ile Ile Glu Gly Asn Thr Ser Glu Asn Lys 595 600 605 Gly Asp Tyr Lys Lys Met Ile Tyr Asn Leu Leu Pro Gly Pro Asn Lys 610 615 620 Met Ile Pro Lys Val Phe Leu Ser Ser Lys Thr Gly Val Glu Thr Tyr 625 630 635 640 Lys Pro Ser Ala Tyr Ile Leu Glu Gly Tyr Lys Gln Asn Lys His Leu 645 650 655 Lys Ser Ser Lys Asp Phe Asp Ile Thr Phe Cys His Asp Leu Ile Asp 660 665 670 Tyr Phe Lys Asn Cys Ile Ala Ile His Pro Glu Trp Lys Asn Phe Gly 675 680 685 Phe Asp Phe Ser Asp Thr Ser Thr Tyr Glu Asp Ile Ser Gly Phe Tyr 690 695 700 Arg Glu Val Glu Leu Gln Gly Tyr Lys Ile Asp Trp Thr Tyr Ile Ser 705 710 715 720 Glu Lys Asp Ile Asp Leu Leu Gln Glu Lys Gly Gln Leu Tyr Leu Phe 725 730 735 Gln Ile Tyr Asn Lys Asp Phe Ser Lys Lys Ser Thr Gly Asn Asp Asn 740 745 750 Leu His Thr Met Tyr Leu Lys Asn Leu Phe Ser Glu Glu Asn Leu Lys 755 760 765 Asp Ile Val Leu Lys Leu Asn Gly Glu Ala Glu Ile Phe Phe Arg Lys 770 775 780 Ser Ser Ile Lys Asn Pro Ile Ile His Lys Lys Gly Ser Ile Leu Val 785 790 795 800 Asn Arg Thr Tyr Glu Ala Glu Glu Lys Asp Gln Phe Gly Asn Ile Gln 805 810 815 Ile Val Arg Lys Thr Ile Pro Glu Asn Ile Tyr Gln Glu Leu Tyr Lys 820 825 830 Tyr Phe Asn Asp Lys Ser Asp Lys Glu Leu Ser Asp Glu Ala Ala Lys 835 840 845 Leu Lys Asn Val Val Gly His His Glu Ala Ala Thr Asn Ile Val Lys 850 855 860 Asp Tyr Arg Tyr Thr Tyr Asp Lys Tyr Phe Leu His Met Pro Ile Thr 865 870 875 880 Ile Asn Phe Lys Ala Asn Lys Thr Ser Phe Ile Asn Asp Arg Ile Leu 885 890 895 Gln Tyr Ile Ala Lys Glu Lys Asn Leu His Val Ile Gly Ile Asp Arg 900 905 910 Gly Glu Arg Asn Leu Ile Tyr Val Ser Val Ile Asp Thr Cys Gly Asn 915 920 925 Ile Val Glu Gln Lys Ser Phe Asn Ile Val Asn Gly Tyr Asp Tyr Gln 930 935 940 Ile Lys Leu Lys Gln Gln Glu Gly Ala Arg Gln Ile Ala Arg Lys Glu 945 950 955 960 Trp Lys Glu Ile Gly Lys Ile Lys Glu Ile Lys Glu Gly Tyr Leu Ser 965 970 975 Leu Val Ile His Glu Ile Ser Lys Met Val Ile Lys Tyr Asn Ala Ile 980 985 990 Ile Ala Met Glu Asp Leu Ser Tyr Gly Phe Lys Lys Gly Arg Phe Lys 995 1000 1005 Val Glu Arg Gln Val Tyr Gln Lys Phe Glu Thr Met Leu Ile Asn Lys 1010 1015 1020 Leu Asn Tyr Leu Val Phe Lys Asp Ile Ser Ile Thr Glu Asn Gly Gly 1025 1030 1035 1040 Leu Leu Lys Gly Tyr Gln Leu Thr Tyr Ile Pro Asp Lys Leu Lys Asn 1045 1050 1055 Val Gly His Gln Cys Gly Cys Ile Phe Tyr Val Pro Ala Ala Tyr Thr 1060 1065 1070 Ser Lys Ile Asp Pro Thr Thr Gly Phe Val Asn Ile Phe Lys Phe Lys 1075 1080 1085 Asp Leu Thr Val Asp Ala Lys Arg Glu Phe Ile Lys Lys Phe Asp Ser 1090 1095 1100 Ile Arg Tyr Asp Ser Glu Lys Lys Leu Phe Cys Phe Thr Phe Asp Tyr 1105 1110 1115 1120 Asn Asn Phe Ile Thr Gln Asn Thr Val Met Ser Lys Ser Ser Trp Ser 1125 1130 1135 Val Tyr Thr Tyr Gly Val Arg Ile Lys Arg Arg Phe Val Asn Gly Arg 1140 1145 1150 Phe Ser Asn Glu Ser Asp Thr Ile Asp Ile Thr Lys Asp Met Glu Lys 1155 1160 1165 Thr Leu Glu Met Thr Asp Ile Asn Trp Arg Asp Gly His Asp Leu Arg 1170 1175 1180 Gln Asp Ile Ile Asp Tyr Glu Ile Val Gln His Ile Phe Glu Ile Phe 1185 1190 1195 1200 Arg Leu Thr Val Gln Met Arg Asn Ser Leu Ser Glu Leu Glu Asp Arg 1205 1210 1215 Asp Tyr Asp Arg Leu Ile Ser Pro Val Leu Asn Glu Asn Asn Ile Phe 1220 1225 1230 Tyr Asp Ser Ala Lys Ala Gly Asp Ala Leu Pro Lys Asp Ala Asp Ala 1235 1240 1245 Asn Gly Ala Tyr Cys Ile Ala Leu Lys Gly Leu Tyr Glu Ile Lys Gln 1250 1255 1260 Ile Thr Glu Asn Trp Lys Glu Asp Gly Lys Phe Ser Arg Asp Lys Leu 1265 1270 1275 1280 Lys I Asn Lys Asp Trp Phe Asp Phe Ile Gln Asn Lys Arg Tyr 1285 1290 1295 Leu Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser 1300 1305 1310 Pro Ala Ala Lys A rg Val Lys Leu Asp Gly Gly Ser Pro Ala Ala Lys 1315 1320 1325 Arg Val Lys Leu Asp Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu 1330 1335 1340 Asp Gly Gly Ser Pro Ala Ala Lys Arg Val Lys Leu Asp Gly Gly Ser 1345 1350 1355 1360 Pro Ala Ala Lys Arg Val Lys Leu Asp Ala Ser Gly Ser His His His His 1365 1370 1375 His His His <210> 20 <211> 4140 <212> DNA <213> Artificial Sequence <220> <223> opmgCas12a -1-6XNLS <400> 20 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atggctagca tgactggtgg acagcaaatg ggtcgcggat ccatgaacaa tggcaccaac 120 aatttccaga actttatcgg aattagcagt ctgcaaaaga ctctccggaa tgcccttata 180 cccaccgaga caacccagca gttcatcgtg aaaaacggga ttatcaagga agacgagctg 240 cgcggcgaaa atcggcaaat tttgaaagat ataatggacg attattaccg cggttttatc 300 tctgagactc tgagctccat tgacgatatc gactggacct cactcttcga aaagatggag 360 attcagctta aaaacggcga taataaggac acactgataa aagaacaggc tgagaagcgg 420 aaagccatct ataagaaatt tgcagatgac gatcgcttca agaacatgtt tagcgccaaa 480 ttgattagtg acatcctgcc ggaattc gtt attcacaata acaattactc tgctagcgag 540 aaggaagaga aaacccaagt cataaagctc ttttcccggt tcgccacttc atttaaagat 600 tatttccgca accgcgcaaa ttgctttagc gccgacgata tcagttctag ctcctgtcat 660 cggattgtga acgacaatgc tgaaatcttc ttttcaaacg cccttgtata ccgccggatt 720 gtgaaaaatc tgagcaacga tgacataaat aagatcagtg gagatattaa agactctttg 780 aaggagatga gcctggaaga gatctattcc tacgaaaaat atggggagtt cattacccag 840 gaaggcatat cattttacaa cgatatctgc ggtaaggtta atagcttcat gaacctctat 900 tgtcagaaaa ataaggagaa caaaaatctt tacaagctgc gcaaattgca caagcaaatt 960 ctgtgcatcg cagacacaag ttatgaagtc ccttacaaat ttgagtctga tgaagaggtg 1020 tatcagagcg taaacggctt cctcgacaat atttcctcaa agcatatagt ggaacggctt 1080 cgcaaaatcg gagataacta caatgggtat aacctggaca agatttacat cgttagcaaa 1140 ttttatgaga gtgtctctca gaagacctac cgggattggg aaactattaa taccgccttg 1200 gagatacact ataacaatat cctgcccggc aacggtaaaa gcaaggctga caaagtgaag 1260 aaagccgtaa agaatgatct ccaaaaatcc attacagaaa tcaacgagct tgtgtcaaat 1320 tacaagctgt gtccggacga taacattaaa gcagaaacct atatacatga gatcagccac 1380 attttgaata acttcgaagc ccaggagctg aagtacaatc cagaaatcca tctcgttgag 1440 agtgaactta aagcttctga gctgaagaac gtcttggacg tgattatgaa tgcctttcac 1500 tggtgcagcg tattcatgac tgaagagctg gtggataaag acaacaattt ttatgcagaa 1560 ctcgaggaaa tatacgatga gatctatacc gttatttccc tttacaacct ggtccgcaat 1620 tatgtgacac agaagcccta ctcaaccaaa aagatcaaat tgaacttcgg cattccgact 1680 ctggcccgcg gatggagcaa gagtaaagaa tattctaata acgctataat cctcatgcgg 1740 gataatcttt actatctggg gatttttaac gccaagaata aacctgacaa gaaaatcatt 1800 gagggcaaca ccagcgaaaa taagggtgat tacaaaaaga tgatatataa cttgctgccc 1860 ggcccgaata aaatgatccc aaaggtattc ctctcctcaa aaacaggagt ggagacctac 1920 aagcccagcg catatattct tgaagggtac aaacaaaaca agcatctgaa aagttctaag 1980 gactttgata tcactttctg tcacgacttg attgattatt ttaaaaattg catagccatc 2040 catccggagt ggaagaactt cggctttgac ttcagcgata cctccacata cgaagacatt 2100 tcaggttttt atcgcgaggt tgaactgcag ggctacaaaa tcgattggac ctatattagc 2160 gagaaggaca tagatctcct tcaggaaaaa ggacaactgt acttg ttcca gatctataat 2220 aaggacttta gtaaaaagtc tactgggaac gataatctgc acaccatgta cctcaaaaac 2280 cttttcagcg aggaaaatct gaaggacatt gtcttgaaac tgaacggcga ggctgaaatc 2340 tttttccgga agtcctcaat taaaaatcct ataatccata agaaaggtag cattctcgtg 2400 aaccgcacat atgaggccga agagaaggat cagtttggca atatccaaat tgtacggaaa 2460 accatacccg aaaacatcta ccaggagctt tataagtact tcaatgacaa aagtgataag 2520 gaactgtctg acgaggcagc caaattgaag aacgtggttg gacaccatga agctgccact 2580 aatattgtca aagattatcg ctacacctat gacaagtact ttctgcacat gccgatcaca 2640 attaacttca aagcaaataa gaccagcttt ataaacgatc ggattctcca gtatattgcc 2700 aaagagaaga atcttcatgt gatcgggatt gaccgcggcg aacggaacct gatatacgta 2760 tccgtgatcg atacttgtgg taatattgtt gagcaaaaat cattcaacat cgtcaatggc 2820 tatgactacc agattaagtt gaaacagcaa gaaggagctc gccagatagc ccggaaggag 2880 tggaaggaaa tcgggaaaat taaggagatc aaagaaggct atctgagcct cgtgattcac 2940 gagataagta agatggtaat caaatacaac gcaattatcg ccatggaaga tctttcttat 3000 ggttttaaga aaggccgctt caaggtggag cggcaagttt accagaaatt tgaaaccatg 3060 ctgattaata agttgaacta tctggtcttc aaagacataa gcatcacaga gaatggaggg 3120 ctccttaagg gctaccagct gacctatatt ccagataaat tgaagaacgt gggtcatcaa 3180 tgcggctgta tcttttacgt acccgctgcc tatacttcca aaattgaccc gaccacagga 3240 ttcgtgaata tatttaagtt caaagatctg accgttgacg caaagcgcga atttatcaaa 3300 aagttcgatt caattcggta cgacagcgag aaaaagctct tttgcttcac ttttgattat 3360 aacaatttca tcacccagaa cacagtcatg agtaaatcta gctggtccgt gtacacctat 3420 ggggtacgca ttaagcggcg ctttgtgaat ggccggttct caaacgaaag cgacactata 3480 gatatcacca aagacatgga gaagacactt gaaatgaccg atattaattg gcgcgacggt 3540 cacgatctgc ggcaggacat cattgattac gagatagttc aacatatctt tgaaattttc 3600 cgcttgactg tccagatgcg gaacagtctg tctgagctcg aagaccgcga ttatgaccgg 3660 cttatcagcc ctgtgctgaa tgagaacaat attttttacg attccgccaa agctggcgac 3720 gccttgccca aggatgcaga cgccaacgga gcttattgta tagccctgaa agggctctac 3780 gaaatcaagc agattaccga gaattggaaa gaagatggca agttctcacg cgacaaactt 3840 aagatcagca acaaagattg gtttgacttc attcaaaata agcggtatct gggcgg ctcc 3900 cctgctgcta aacgtgttaa gcttgatggg ggtagcccgg cagccaagag agtcaaactc 3960 gacggcggct ccccagcggc aaaaagggtg aaactagacg ggggtagccc cgccgcgaag 4020 cgtgtaaagc tggatggagg atcgcctgcg gctaagcgag tcaaattaga cggtgggtca 4080 ccggctgcaa agcgcgtcaa attggatgct agcggcagcc accaccacca ccaccactga 4140 4140 <210> 21 <211> 21 <212> DNA <213> Artificial Sequence <220 > <223> HPRT1<400> 21 ggttaaagat ggttaaatga t 21

Claims (11)

Cas12a 단백질 또는 이를 암호화하는 DNA;
표적 뉴클레오티드(target nucleotide) 서열과 혼성화 가능한 뉴클레오티드 서열을 포함하는 가이드 RNA 또는 이를 암호화하는 DNA; 및
인핸서(enhancer)
를 포함하는 유전체 편집용 조성물.
Cas12a protein or DNA encoding the same;
a guide RNA comprising a nucleotide sequence capable of hybridizing with a target nucleotide sequence or a DNA encoding the same; and
enhancer
A composition for genome editing comprising a.
 제 1 항에 있어서, 상기 Cas12a 단백질은
서열번호 1의 아미노산 서열로 이루어진 단백질; 및
상기 단백질의 C-말단에 서열번호 4로 이루어진 myc-NLS(nuclear localization sequences)가 연결된 Cas12a 단백질
인 것인 유전체 편집용 조성물.
The method of claim 1, wherein the Cas12a protein is
a protein consisting of the amino acid sequence of SEQ ID NO: 1; and
Cas12a protein linked to myc-NLS (nuclear localization sequences) consisting of SEQ ID NO: 4 to the C-terminus of the protein
A composition for genome editing that is
 제 2 항에 있어서, 상기 연결은 Gly-Gly-Ser 아미노산 서열에 의한 것인 유전체 편집용 조성물.
The composition for genome editing according to claim 2, wherein the linkage is by a Gly-Gly-Ser amino acid sequence.
 제 2 항에 있어서, 상기 myc-NLS는 2 내지 10개가 반복연결된 것인 유전체 편집용 조성물.
The composition for genome editing according to claim 2, wherein 2 to 10 of the myc-NLS are repeatedly linked.
 제 2 항에 있어서, 상기 myc-NLS는 6개가 반복연결된 것인 유전체 편집용 조성물.
The composition for genome editing according to claim 2, wherein 6 of the myc-NLS are repeatedly linked.
 제 4 항 또는 제 5 항에 있어서, 상기 myc-NLS는 각각 Gly-Gly-Ser 아미노산 서열로 연결된 것인 유전체 편집용 조성물.
The composition for editing a genome according to claim 4 or 5, wherein the myc-NLS is linked by a Gly-Gly-Ser amino acid sequence, respectively.
 제 2 항에 있어서, 상기 서열번호 1의 아미노산 서열 중 169번째 위치의 라이신(Lys)이 아르기닌(Arg)으로 치환된 것인 유전체 편집용 조성물.
The composition for genome editing according to claim 2, wherein lysine (Lys) at position 169 in the amino acid sequence of SEQ ID NO: 1 is substituted with arginine (Arg).
 제 2 항에 있어서, 상기 서열번호 1의 아미노산 서열 중 529번째 위치의 아스파르트산(Asp)이 아르기닌(Arg)으로 치환된 것인 유전체 편집용 조성물.
The composition for genome editing according to claim 2, wherein aspartic acid (Asp) at position 529 in the amino acid sequence of SEQ ID NO: 1 is substituted with arginine (Arg).
 제 2 항에 있어서, 상기 Cas12a 단백질은 서열번호 19의 아미노산 서열로 이루어진 것인 유전체 편집용 조성물.
The composition for genome editing according to claim 2, wherein the Cas12a protein consists of the amino acid sequence of SEQ ID NO: 19.
 제 1 항의 유전체 편집용 조성물을 분리된 세포 또는 유기체에 도입하는 단계를 포함하는 유전체 편집 방법.
A genome editing method comprising the step of introducing the composition for genome editing of claim 1 into an isolated cell or organism.
 제 1 항의 유전체 편집용 조성물을 분리된 세포 또는 인간을 제외한 유기체에 도입하는 단계를 포함하는 형질 전환체의 제조 방법.A method for producing a transformant comprising the step of introducing the composition for genome editing of claim 1 into isolated cells or organisms other than humans.
KR1020200121990A 2020-09-22 2020-09-22 Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof KR20220039189A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020200121990A KR20220039189A (en) 2020-09-22 2020-09-22 Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof
US18/027,598 US20230374478A1 (en) 2020-09-22 2021-09-23 Modified cas12a protein and use thereof
PCT/KR2021/012936 WO2022065867A1 (en) 2020-09-22 2021-09-23 Modified cas12a protein and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200121990A KR20220039189A (en) 2020-09-22 2020-09-22 Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof

Publications (1)

Publication Number Publication Date
KR20220039189A true KR20220039189A (en) 2022-03-29

Family

ID=80997288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200121990A KR20220039189A (en) 2020-09-22 2020-09-22 Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof

Country Status (1)

Country Link
KR (1) KR20220039189A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101828933B1 (en) 2014-11-14 2018-02-14 기초과학연구원 Method for detecting genome-wide off-target sites of programmable nucleases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101828933B1 (en) 2014-11-14 2018-02-14 기초과학연구원 Method for detecting genome-wide off-target sites of programmable nucleases

Similar Documents

Publication Publication Date Title
CN106922154B (en) Gene editing using Campylobacter jejuni CRISPR/CAS system-derived RNA-guided engineered nucleases
US20230416310A1 (en) Inducible, Tunable, and Multiplex Human Gene Regulation Using CRISPR-Cpf1
US7528245B2 (en) Efficient protein expression system
KR101889589B1 (en) Modified cascade ribonucleoproteins and uses thereof
KR20190082318A (en) CRISPR / CPF1 system and method
KR20230169449A (en) Rna-guided nucleic acid modifying enzymes and methods of use thereof
KR20190005801A (en) Target Specific CRISPR variants
KR102626503B1 (en) Target sequence-specific modification technology using nucleotide target recognition
US20210292722A1 (en) Novel crispr-associated protein and use thereof
WO2023098485A1 (en) C2c9 nuclease-based novel genome editing system and application thereof
WO2020207286A1 (en) Rna site-directed editing using artificially constructed rna editing enzymes and related uses
US20230374478A1 (en) Modified cas12a protein and use thereof
KR102497690B1 (en) Novel CRISPR Associated Protein and Use thereof
KR20220039189A (en) Composition for Genome Editing comprising Novel CRISPR Associated Protein and Enhancer, and use thereof
KR101841264B1 (en) Recombinant Vector Including Gene of Autopahgy Activation Protein and Crystallizing Method for Recombinant Protein Using Thereof
KR20180128864A (en) Gene editing composition comprising sgRNAs with matched 5&#39; nucleotide and gene editing method using the same
RU2771626C1 (en) Tool for cutting double-stranded dna using cas12d protein from katanobacteria and hybrid rna produced by fusion of guide crispr rna and scout rna
KR102176415B1 (en) Recombinant Protein for Penetrating within Prokaryotic Cell and The Uses Thereof
RU2788197C1 (en) DNA-CUTTING AGENT BASED ON Cas9 PROTEIN FROM THE BACTERIUM STREPTOCOCCUS UBERIS NCTC3858
WO2024080067A1 (en) Genome editing method and composition for genome editing
US20230242922A1 (en) Gene editing tools
WO2023206872A1 (en) Engineering-optimized nuclease, guide rna, editing system, and use
WO2021249536A1 (en) Engineered bacterium containing barstar gene and use thereof in barnase gene cloning
CN113614247A (en) DNA cleavage agent
WO2021096391A1 (en) Use of cas9 protein from the bacterium pasteurella pneumotropica